
David B Price

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/7050911/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Perceptions, attitudes, and behaviors of short-acting beta ₂ agonist users: an Australian cross-sectional community pharmacy-based study. Journal of Asthma, 2022, 59, 178-188.	0.9	7
2	Short-acting β ₂ -agonist prescriptions are associated with poor clinical outcomes of asthma: the multi-country, cross-sectional SABINA III study. European Respiratory Journal, 2022, 59, 2101402.	3.1	50
3	Treatment Trials in Young Patients with Chronic Obstructive Pulmonary Disease and Pre–Chronic Obstructive Pulmonary Disease Patients: Time to Move Forward. American Journal of Respiratory and Critical Care Medicine, 2022, 205, 275-287.	2.5	72
4	Oral corticosteroid elimination via a personalised reduction algorithm in adults with severe, eosinophilic asthma treated with benralizumab (PONENTE): a multicentre, open-label, single-arm study. Lancet Respiratory Medicine,the, 2022, 10, 47-58.	5.2	74
5	Ethnic Differences in Severe Asthma Clinical Care and Outcomes: An Analysis of United Kingdom Primary and Specialist Care. Journal of Allergy and Clinical Immunology: in Practice, 2022, 10, 495-505.e2.	2.0	14
6	Measuring Peak Inspiratory Flow in Patients with Chronic Obstructive Pulmonary Disease. International Journal of COPD, 2022, Volume 17, 79-92.	0.9	8
7	Prioritising primary care respiratory research needs: results from the 2020 International Primary Care Respiratory Group (IPCRG) global e-Delphi exercise. Npj Primary Care Respiratory Medicine, 2022, 32, 6.	1.1	9
8	Real World Biologic Use and Switch Patterns in Severe Asthma: Data from the International Severe Asthma Registry and the US CHRONICLE Study. Journal of Asthma and Allergy, 2022, Volume 15, 63-78.	1.5	41
9	Reducing asthma attacks in children using exhaled nitric oxide (RAACENO) as a biomarker to inform treatment strategy: a multicentre, parallel, randomised, controlled, phase 3 trial. Lancet Respiratory Medicine,the, 2022, 10, 584-592.	5.2	11
10	Global Variability in Administrative Approval Prescription Criteria for Biologic Therapy in Severe Asthma. Journal of Allergy and Clinical Immunology: in Practice, 2022, 10, 1202-1216.e23.	2.0	22
11	Interclass Difference in Pneumonia Risk in COPD Patients Initiating Fixed Dose Inhaled Treatment Containing Extrafine Particle Beclometasone versus Fine Particle Fluticasone. International Journal of COPD, 2022, Volume 17, 355-370.	0.9	5
12	Reply to: Cause or consequence?. European Respiratory Journal, 2022, 59, 2200103.	3.1	1
13	Clinical Remission in Severe Asthma: A Pooled Post Hoc Analysis of the Patient Journey with Benralizumab. Advances in Therapy, 2022, 39, 2065-2084.	1.3	47
14	A Pooled Analysis of Mortality in Patients with COPD Receiving Dual Bronchodilation with and without Additional Inhaled Corticosteroid. International Journal of COPD, 2022, Volume 17, 545-558.	0.9	11
15	Use of the oral beta blocker bisoprolol to reduce the rate of exacerbation in people with chronic obstructive pulmonary disease (COPD): a randomised controlled trial (BICS). Trials, 2022, 23, 307.	0.7	2
16	Quality Standard Position Statements for Health System Policy Changes in Diagnosis and Management of COPD: A Global Perspective. Advances in Therapy, 2022, 39, 2302-2322.	1.3	5
17	Variation in Demographic and Clinical Characteristics of Patients with COPD Receiving Care in US Primary Care: Data from the Advancing the Patient EXperience (APEX) in COPD Registry. Journal of Pragmatic and Observational Research, 2022, Volume 13, 17-31.	1.1	0
18	Factors associated with health status and exacerbations in COPD maintenance therapy with dry powder inhalers. Npj Primary Care Respiratory Medicine, 2022, 32, .	1.1	10

#	Article	IF	CITATIONS
19	Treatment guided by fractional exhaled nitric oxide in addition to standard care in 6- to 15-year-olds with asthma: the RAACENO RCT. Efficacy and Mechanism Evaluation, 2022, 9, 1-154.	0.9	1
20	Biologics in severe asthma: the role of real-world evidence from registries. European Respiratory Review, 2022, 31, 210278.	3.0	13
21	Reducing the hidden burden of severe asthma: recognition and referrals from primary practice. Journal of Asthma, 2021, 58, 849-854.	0.9	8
22	Identifying patients at risk of poor asthma outcomes associated with making inhaler technique errors. Journal of Asthma, 2021, 58, 967-978.	0.9	11
23	ARIA digital anamorphosis: Digital transformation of health and care in airway diseases from research to practice. Allergy: European Journal of Allergy and Clinical Immunology, 2021, 76, 168-190.	2.7	46
24	Treatment patterns among non-active users of maintenance asthma medication in the United Kingdom: a retrospective cohort study in the Clinical Practice Research Datalink. Journal of Asthma, 2021, 58, 793-804.	0.9	13
25	Hormone replacement therapy and asthma onset in menopausal women: National cohort study. Journal of Allergy and Clinical Immunology, 2021, 147, 1662-1670.	1.5	20
26	Hormonal contraception and the risk of severe asthma exacerbation: 17-year population-based cohort study. Thorax, 2021, 76, 109-115.	2.7	18
27	Expert Consensus on the Tapering of Oral Corticosteroids for the Treatment of Asthma. A Delphi Study. American Journal of Respiratory and Critical Care Medicine, 2021, 203, 871-881.	2.5	65
28	Development of the Advancing the Patient Experience in COPD Registry: A Modified Delphi Study. Chronic Obstructive Pulmonary Diseases (Miami, Fla), 2021, 8, 135-151.	0.5	3
29	Withdrawal of inhaled corticosteroids versus continuation of triple therapy in patients with COPD in real life: observational comparative effectiveness study. Respiratory Research, 2021, 22, 25.	1.4	15
30	Changes in Control Status of COPD Over Time and Their Consequences: A Prospective International Study. Archivos De Bronconeumologia, 2021, 57, 122-129.	0.4	1
31	Specialist respiratory outreach: a case-finding initiative for identifying undiagnosed COPD in primary care. Npj Primary Care Respiratory Medicine, 2021, 31, 7.	1.1	8
32	Heterogeneity within and between physician-diagnosed asthma and/or COPD: NOVELTY cohort. European Respiratory Journal, 2021, 58, 2003927.	3.1	43
33	Changes in Control Status of COPD Over Time and Their Consequences: A Prospective International Study. Archivos De Bronconeumologia, 2021, 57, 122-129.	0.4	21
34	Childhood asthma outcomes during the COVIDâ€19 pandemic: Findings from the PeARL multiâ€national cohort. Allergy: European Journal of Allergy and Clinical Immunology, 2021, 76, 1765-1775.	2.7	62
35	Hormone Replacement Therapy and Risk of Severe Asthma Exacerbation in Perimenopausal and Postmenopausal Women: 17-Year National Cohort Study. Journal of Allergy and Clinical Immunology: in Practice, 2021, 9, 2751-2760.e1.	2.0	12
36	Cluster Analysis of Inflammatory Biomarker Expression in the International Severe Asthma Registry. Journal of Allergy and Clinical Immunology: in Practice, 2021, 9, 2680-2688.e7.	2.0	50

#	Article	IF	CITATIONS
37	Potential Severe Asthma Hidden in UK Primary Care. Journal of Allergy and Clinical Immunology: in Practice, 2021, 9, 1612-1623.e9.	2.0	42
38	Burden of allergic rhinitis and impact of MP-AzeFlu from the patient perspective: pan European patient survey. Current Medical Research and Opinion, 2021, 37, 1259-1272.	0.9	3
39	Longâ€ŧerm corticosteroid use, adrenal insufficiency and the need for steroidâ€sparing treatment in adult severe asthma. Journal of Internal Medicine, 2021, 290, 240-256.	2.7	18
40	OCS Reduction According to the Presence of Nasal Polyps or Atopic Status in the PONENTE Study. , 2021, , .		0
41	Maximizing Adherence and Gaining New Information For Your Chronic Obstructive Pulmonary Disease (MAGNIFY COPD): Study Protocol for the Pragmatic, Cluster Randomized Trial Evaluating the Impact of Dual Bronchodilator with Add-On Sensor and Electronic Monitoring on Clinical Outcomes. Journal of Pragmatic and Observational Research. 2021. Volume 12. 25-35.	1.1	5
42	Characterization of COPD in U.S. Primary Care: Data from a Real-Life COPD Registry. , 2021, , .		0
43	Adrenal Insufficiency Is Not a Barrier to OCS Elimination in the PONENTE Study. , 2021, , .		0
44	Validation of the Chronic Airways Assessment Test in the NOVELTY Study. , 2021, , .		0
45	Persistence of Eosinophilic Asthma Endotype and Clinical Outcomes: A Real-World Observational Study. Journal of Asthma and Allergy, 2021, Volume 14, 727-742.	1.5	9
46	Artificial Intelligence/Machine Learning in Respiratory Medicine and Potential Role in Asthma and COPD Diagnosis. Journal of Allergy and Clinical Immunology: in Practice, 2021, 9, 2255-2261.	2.0	76
47	The influence of individual characteristics and nonâ€respiratory diseases on blood eosinophil count. Clinical and Translational Allergy, 2021, 11, e12036.	1.4	5
48	Predicting asthma-related crisis events using routine electronic healthcare data: a quantitative database analysis study. British Journal of General Practice, 2021, 71, e948-e957.	0.7	12
49	High Use of SABAs is Associated with Higher Exacerbation Rate in Dutch Patients with Asthma. Journal of Asthma and Allergy, 2021, Volume 14, 851-861.	1.5	9
50	Management of asthma in childhood: study protocol of a systematic evidence update by the Paediatric Asthma in Real Life (PeARL) Think Tank. BMJ Open, 2021, 11, e048338.	0.8	2
51	Defining a Severe Asthma Super-Responder: Findings from a Delphi Process. Journal of Allergy and Clinical Immunology: in Practice, 2021, 9, 3997-4004.	2.0	74
52	Asthma Phenotyping in Primary Care: Applying the International Severe Asthma Registry Eosinophil Phenotype Algorithm Across All Asthma Severities. Journal of Allergy and Clinical Immunology: in Practice, 2021, 9, 4353-4370.	2.0	12
53	CONQUEST Quality Standards: For the Collaboration on Quality Improvement Initiative for Achieving Excellence in Standards of COPD Care. International Journal of COPD, 2021, Volume 16, 2301-2322.	0.9	9
54	Risk Predictors and Symptom Features of Long COVID Within a Broad Primary Care Patient Population Including Both Tested and Untested Patients. Journal of Pragmatic and Observational Research, 2021, Volume 12, 93-104.	1.1	32

#	Article	IF	CITATIONS
55	Eosinophilic and Noneosinophilic Asthma. Chest, 2021, 160, 814-830.	0.4	109
56	Association Between a Type 2 Inflammatory Disease Burden Score and Outcomes Among Patients with Asthma. Journal of Asthma and Allergy, 2021, Volume 14, 1173-1183.	1.5	12
57	Why We Should Target Small Airways Disease in Our Management of Chronic Obstructive Pulmonary Disease. Mayo Clinic Proceedings, 2021, 96, 2448-2463.	1.4	21
58	The cardiovascular phenotype of Chronic Obstructive Pulmonary Disease (COPD): Applying machine learning to the prediction of cardiovascular comorbidities. Respiratory Medicine, 2021, 186, 106528.	1.3	6
59	Impact of PIF, Inhalation Technique and Medication Adherence on Health Status and Exacerbations in COPD: Protocol of a Real-World Observational Study (PIFotal COPD Study). Pulmonary Therapy, 2021, 7, 591-606.	1.1	9
60	A real-life comparative effectiveness study into the addition of antibiotics to the management of asthma exacerbations in primary care. European Respiratory Journal, 2021, 58, 2003599.	3.1	11
61	Patient perceptions of the re-usable Respimat [®] Soft Mistâ,,¢ inhaler in current users and those switching to the device: A real-world, non-interventional COPD study. Chronic Respiratory Disease, 2021, 18, 147997312098622.	1.0	3
62	Characteristics of patients in platform C19, a COVID-19 research database combining primary care electronic health record and patient reported information. PLoS ONE, 2021, 16, e0258689.	1.1	2
63	Fast decliner phenotype of chronic obstructive pulmonary disease (COPD): applying machine learning for predicting lung function loss. BMJ Open Respiratory Research, 2021, 8, e000980.	1.2	4
64	Validation of a diagnosis-agnostic symptom questionnaire for asthma and/or COPD. ERJ Open Research, 2021, 7, 00828-2020.	1.1	6
65	Impact of Socioeconomic Status on Adult Patients with Asthma: A Population-Based Cohort Study from UK Primary Care. Journal of Asthma and Allergy, 2021, Volume 14, 1375-1388.	1.5	13
66	Systematic Literature Review of Systemic Corticosteroid Use for Asthma Management. American Journal of Respiratory and Critical Care Medicine, 2020, 201, 276-293.	2.5	182
67	Next-generation Allergic Rhinitis and Its Impact on Asthma (ARIA) guidelines for allergic rhinitis based on Grading of Recommendations Assessment, Development and Evaluation (GRADE) and real-world evidence. Journal of Allergy and Clinical Immunology, 2020, 145, 70-80.e3.	1.5	272
68	Pointâ€ofâ€care biomarkers in asthma management: Time to move forward. Allergy: European Journal of Allergy and Clinical Immunology, 2020, 75, 995-997.	2.7	13
69	The Relationship Between Real-World Inhaled Corticosteroid Adherence and Asthma Outcomes: A Multilevel Approach. Journal of Allergy and Clinical Immunology: in Practice, 2020, 8, 626-634.	2.0	19
70	Comparative Safety Profile of the Fixed-Dose Combination Corticosteroid and Long-acting β2-Agonist Fluticasone Propionate/Formoterol Fumarate: A 36-Month Longitudinal Cohort Study in UK Primary Care. Drugs, 2020, 80, 47-60.	4.9	7
71	International Severe Asthma Registry. Chest, 2020, 157, 805-814.	0.4	38
72	Characterization of Severe Asthma Worldwide. Chest, 2020, 157, 790-804.	0.4	165

#	Article	IF	CITATIONS
73	The Role of Aeroallergen Sensitization Testing in Asthma Management. Journal of Allergy and Clinical Immunology: in Practice, 2020, 8, 2526-2532.	2.0	8
74	Extrafine Beclometasone Dipropionate/Formoterol Fumarate vs Double Bronchodilation Therapy in Patients with COPD: A Historical Real-World Non-Inferiority Study. International Journal of COPD, 2020, Volume 15, 2739-2750.	0.9	0
75	Impact of allergic rhinitis on the day-to-day lives of children: insights from an Australian cross-sectional study. BMJ Open, 2020, 10, e038870.	0.8	5
76	A Comparison of the Real-Life Clinical Effectiveness of the Leading Licensed ICS/LABA Combination Inhalers in the Treatment for COPD. International Journal of COPD, 2020, Volume 15, 3093-3103.	0.9	0
77	<p>MP-AzeFlu Improves the Quality-of-Life of Patients with Allergic Rhinitis</p> . Journal of Asthma and Allergy, 2020, Volume 13, 633-645.	1.5	8
78	COPD phenotypes and machine learning cluster analysis: A systematic review and future research agenda. Respiratory Medicine, 2020, 171, 106093.	1.3	19
79	<p>The Burden of Self-Reported Rhinitis and Associated Risk for Exacerbations with Moderate-Severe Asthma in Primary Care Patients</p> . Journal of Asthma and Allergy, 2020, Volume 13, 415-428.	1.5	10
80	Effect of Specific Immunoglobulin E Response and Comorbidities on Effectiveness of MP-AzeFlu in a Real-Life Study. International Archives of Allergy and Immunology, 2020, 181, 754-764.	0.9	2
81	<clinical and="" associated="" copd<br="" early="" healthcare="" impact="" late="" resource="" utilization="" versus="" with="">Diagnosis in Patients from UK CPRD Database. International Journal of COPD, 2020, Volume 15, 1729-1738.</clinical>	0.9	11
82	Allergic rhinitis and asthma symptoms in a real-life study of MP-AzeFlu to treat multimorbid allergic rhinitis and asthma. Clinical and Molecular Allergy, 2020, 18, 15.	0.8	11
83	International severe asthma registry (ISAR): protocol for a global registry. BMC Medical Research Methodology, 2020, 20, 212.	1.4	29
84	<p>The Long-Term Burden of COPD Exacerbations During Maintenance Therapy and Lung Function Decline</p> . International Journal of COPD, 2020, Volume 15, 1909-1918.	0.9	17
85	Observational studies assessing the pharmacological treatment of obstructive lung disease: strengths, challenges and considerations for study design. ERJ Open Research, 2020, 6, 00044-2020.	1.1	4
86	Opportunities to diagnose fibrotic lung diseases in routine care: A primary care cohort study. Respirology, 2020, 25, 1274-1282.	1.3	5
87	Association between COPD exacerbations and lung function decline during maintenance therapy. Thorax, 2020, 75, 744-753.	2.7	32
88	Historical database cohort study addressing the clinical patterns prior to idiopathic pulmonary fibrosis (IPF) diagnosis in UK primary care. BMJ Open, 2020, 10, e034428.	0.8	5
89	Research Priorities in Pediatric Asthma: Results of a Global Survey of Multiple Stakeholder Groups by the Pediatric Asthma in Real Life (PeARL) Think Tank. Journal of Allergy and Clinical Immunology: in Practice, 2020, 8, 1953-1960.e9.	2.0	27
90	Adequacy of Therapy for People with Both COPD and Heart Failure in the UK: Historical Cohort Study. Journal of Pragmatic and Observational Research, 2020, Volume 11, 55-66.	1.1	3

#	Article	IF	CITATIONS
91	<p>Treatment Adherence in Adolescents with Asthma</p> . Journal of Asthma and Allergy, 2020, Volume 13, 39-49.	1.5	77
92	Predictive value of control of <scp>COPD</scp> for risk of exacerbations: An international, prospective study. Respirology, 2020, 25, 1136-1143.	1.3	24
93	Short-course systemic corticosteroids in asthma: striking the balance between efficacy and safety. European Respiratory Review, 2020, 29, 190151.	3.0	63
94	Hormonal contraceptives and onset of asthma in reproductive-age women: Population-based cohort study. Journal of Allergy and Clinical Immunology, 2020, 146, 438-446.	1.5	15
95	Evaluating the real-life effect of MP-AzeFlu on asthma outcomes in patients with allergic rhinitis and asthma in UK primary care. World Allergy Organization Journal, 2020, 13, 100490.	1.6	5
96	Blood eosinophil count predicts treatment failure and hospital readmission for COPD. ERJ Open Research, 2020, 6, 00188-2020.	1.1	7
97	Pediatric asthma: An unmet need for more effective, focused treatments. Pediatric Allergy and Immunology, 2019, 30, 7-16.	1.1	56
98	Rhinology future trends: 2017 EUFOREA debate on allergic rhinitis. Rhinology, 2019, 57, 49-56.	0.7	10
99	Healthcare resource utilization and costs associated with incremental systemic corticosteroid exposure in asthma. Allergy: European Journal of Allergy and Clinical Immunology, 2019, 74, 273-283.	2.7	90
100	A Patient-Centered Description of Severe Asthma: Patient Understanding Leading to Assessment for a Severe Asthma Referral (PULSAR). Patient, 2019, 12, 539-549.	1.1	6
101	Inhaled corticosteroids in COPD and onset of type 2 diabetes and osteoporosis: matched cohort study. Npj Primary Care Respiratory Medicine, 2019, 29, 38.	1.1	27
102	<p>Comparison of clinical baseline characteristics between Asian and Western COPD patients in a prospective, international, multicenter study</p> . International Journal of COPD, 2019, Volume 14, 1595-1601.	0.9	11
103	Association of elevated fractional exhaled nitric oxide concentration and blood eosinophil count with severe asthma exacerbations. Clinical and Translational Allergy, 2019, 9, 41.	1.4	46
104	Defining severe obstructive lung disease in the biologic era: an endotype-based approach. European Respiratory Journal, 2019, 54, 1900108.	3.1	12
105	Next-generation ARIA care pathways for rhinitis and asthma: a model for multimorbid chronic diseases. Clinical and Translational Allergy, 2019, 9, 44.	1.4	87
106	Management Of Community-Acquired Pneumonia: An Observational Study In UK Primary Care. Journal of Pragmatic and Observational Research, 2019, Volume 10, 53-65.	1.1	5
107	Reducing Asthma Attacks in Children using Exhaled Nitric Oxide as a biomarker to inform treatment strategy: a randomised trial (RAACENO). Trials, 2019, 20, 573.	0.7	6
108	Distribution, Temporal Stability and Appropriateness of Therapy of Patients With COPD in the UK in Relation to GOLD 2019. EClinicalMedicine, 2019, 14, 32-41.	3.2	37

#	Article	IF	CITATIONS
109	Prospective observational study in patients with obstructive lung disease: NOVELTY design. ERJ Open Research, 2019, 5, 00036-2018.	1.1	29
110	Prevalence and Characteristics of Asthma–Chronic Obstructive Pulmonary Disease Overlap in Routine Primary Care Practices. Annals of the American Thoracic Society, 2019, 16, 1143-1150.	1.5	32
111	Asthma Across Age: Insights From Primary Care. Frontiers in Pediatrics, 2019, 7, 162.	0.9	20
112	Realâ€life effectiveness of inhaler device switch from dry powder inhalers to pressurized metredâ€dose inhalers in patients with asthma treated with ICS/LABA. Respirology, 2019, 24, 972-979.	1.3	13
113	Quality standards in respiratory real-life effectiveness research: the REal Life EVidence AssessmeNt Tool (RELEVANT): report from the Respiratory Effectiveness Group—European Academy of Allergy and Clinical Immunology Task Force. Clinical and Translational Allergy, 2019, 9, 20.	1.4	20
114	The REal Life EVidence AssessmeNt Tool (RELEVANT): development of a novel quality assurance asset to rate observational comparative effectiveness research studies. Clinical and Translational Allergy, 2019, 9, 21.	1.4	24
115	Severe Asthma Global Evaluation (SAGE): An Electronic Platform for Severe Asthma. Journal of Allergy and Clinical Immunology: in Practice, 2019, 7, 1440-1449.	2.0	12
116	Inhaler Devices for Delivery of LABA/LAMA Fixed-Dose Combinations in Patients with COPD. Pulmonary Therapy, 2019, 5, 23-41.	1.1	7
117	Comparison of adverse events associated with different spacers used with non-extrafine beclometasone dipropionate for asthma. Npj Primary Care Respiratory Medicine, 2019, 29, 3.	1.1	2
118	Understanding reliever overuse in patients purchasing over-the-counter short-acting beta ₂ agonists: an Australian community pharmacy-based survey. BMJ Open, 2019, 9, e028995.	0.8	42
119	A multinational observational study identifying primary care patients at risk of overestimation of asthma control. Npj Primary Care Respiratory Medicine, 2019, 29, 43.	1.1	20
120	Comparative effectiveness of triple therapy versus dual bronchodilation in COPD. ERJ Open Research, 2019, 5, 00106-2019.	1.1	21
121	An innovative corticosteroid/long-acting β2-agonist breath-triggered inhaler: facilitating lung delivery of fluticasone propionate/formoterol fumarate for the treatment of asthma. Expert Opinion on Drug Delivery, 2019, 16, 1367-1380.	2.4	6
122	Does Changing Inhaler Device Impact Real-Life Asthma Outcomes? Clinical and Economic Evaluation. Journal of Allergy and Clinical Immunology: in Practice, 2019, 7, 934-942.	2.0	12
123	Development of the International Severe Asthma Registry (ISAR): A Modified Delphi Study. Journal of Allergy and Clinical Immunology: in Practice, 2019, 7, 578-588.e2.	2.0	39
124	Low-dose oral theophylline combined with inhaled corticosteroids for people with chronic obstructive pulmonary disease and high risk of exacerbations: a RCT. Health Technology Assessment, 2019, 23, 1-146.	1.3	7
125	Inhaled Corticosteroids and Placebo Treatment Effects in Adult Patients With Cough: A Systematic Review and Meta-analysis. Allergy, Asthma and Immunology Research, 2019, 11, 856.	1.1	20
126	Suboptimal asthma control among over-the-counter reliever purchasers in the community pharmacy. , 2019, , .		0

#	Article	IF	CITATIONS
127	Reliever overuse when treatable traits go untreated. , 2019, , .		Ο
128	Developing a patient-centred template for asthma reviews: an IMP2ART implementation strategy. , 2019, , \cdot		0
129	Characteristics by physician-assigned severity of asthma, asthma+COPD and COPD patients in the NOVELTY study. , 2019, , .		1
130	Epidemiology of lung function in a global severe asthma population. , 2019, , .		0
131	Management of community-acquired pneumonia in primary care: an observational study. , 2019, , .		0
132	Treatable traits as predictors of SABA overuse in the community. , 2019, , .		0
133	Effect of COPD exacerbations on early lung function decline under maintenance therapy: blood eosinophil count asbiomarker. , 2019, , .		0
134	Quadrupling Inhaled Glucocorticoid Dose to Abort Asthma Exacerbations. New England Journal of Medicine, 2018, 378, 902-910.	13.9	119
135	The Burden of Rhinitis and the Impact of Medication Management within the Community Pharmacy Setting. Journal of Allergy and Clinical Immunology: in Practice, 2018, 6, 1717-1725.	2.0	21
136	Relationship of Inhaled Corticosteroid Adherence to Asthma Exacerbations in Patients with Moderate-to-Severe Asthma. Journal of Allergy and Clinical Immunology: in Practice, 2018, 6, 1989-1998.e3.	2.0	44
137	Onset of Action of the Fixed Combination Intranasal Azelastine-Fluticasone Propionate in an Allergen Exposure Chamber. Journal of Allergy and Clinical Immunology: in Practice, 2018, 6, 1726-1732.e6.	2.0	54
138	Evaluation of criteria for clinical control in a prospective, international, multicenter study of patients with COPD. Respiratory Medicine, 2018, 136, 8-14.	1.3	26
139	Treatment of allergic rhinitis using mobile technology with realâ€world data: The <scp>MASK</scp> observational pilot study. Allergy: European Journal of Allergy and Clinical Immunology, 2018, 73, 1763-1774.	2.7	94
140	Physiotherapy breathing retraining for asthma: a randomised controlled trial. Lancet Respiratory Medicine,the, 2018, 6, 19-28.	5.2	97
141	Identifying Patient Attitudinal Clusters Associated with Asthma Control: The European REALISE Survey. Journal of Allergy and Clinical Immunology: in Practice, 2018, 6, 962-971.	2.0	15
142	Inhaler technique mastery and maintenance in healthcare professionals trained on different devices. Journal of Asthma, 2018, 55, 79-88.	0.9	18
143	Impact of Rhinitis on Work Productivity: A Systematic Review. Journal of Allergy and Clinical Immunology: in Practice, 2018, 6, 1274-1286.e9.	2.0	132
144	Extrafine Versus Fine Inhaled Corticosteroids in Relation to Asthma Control: A Systematic Review and Meta-Analysis of Observational Real-Life Studies. Journal of Allergy and Clinical Immunology: in Practice, 2018, 6, 907-915.e7.	2.0	36

#	Article	IF	CITATIONS
145	The Allergic Rhinitis and its Impact on Asthma (ARIA) score of allergic rhinitis using mobile technology correlates with quality of life: The MASK study. Allergy: European Journal of Allergy and Clinical Immunology, 2018, 73, 505-510.	2.7	77
146	Healthcare resource use and costs of severe, uncontrolled eosinophilic asthma in the UK general population. Thorax, 2018, 73, 116-124.	2.7	116
147	Lack of asthma and rhinitis control in general practitioner-managed patients prescribed fixed-dose combination therapy in Australia. Journal of Asthma, 2018, 55, 684-694.	0.9	43
148	Fractional exhaled nitric oxide as a predictor of response to inhaled corticosteroids in patients with non-specific respiratory symptoms and insignificant bronchodilator reversibility: a randomised controlled trial. Lancet Respiratory Medicine,the, 2018, 6, 29-39.	5.2	96
149	Harmonizing the Nomenclature for Therapeutic Aerosol Particle Size: A Proposal. Journal of Aerosol Medicine and Pulmonary Drug Delivery, 2018, 31, 111-113.	0.7	22
150	Physiological predictors Of peak inspiRatory flow using Observed lung function resultS (POROS): evaluation at discharge among patients hospitalized for a COPD exacerbation. International Journal of COPD, 2018, Volume 13, 3937-3946.	0.9	13
151	Matched cohort study of therapeutic strategies to prevent preschool wheezing/asthma attacks. Journal of Asthma and Allergy, 2018, Volume 11, 309-321.	1.5	11
152	Age and Sex Associations with Systemic Corticosteroid-Induced Morbidity in Asthma. Journal of Allergy and Clinical Immunology: in Practice, 2018, 6, 2014-2023.e2.	2.0	25
153	Effect of Theophylline as Adjunct to Inhaled Corticosteroids on Exacerbations in Patients With COPD. JAMA - Journal of the American Medical Association, 2018, 320, 1548.	3.8	67
154	Inhalation therapy in the next decade: Determinants of adherence to treatment in asthma and COPD. Monaldi Archives for Chest Disease, 2018, 88, 886.	0.3	17
155	Management of allergic rhinitis in the community pharmacy: identifying the reasons behind medication self-selection. Pharmacy Practice, 2018, 16, 1332.	0.8	16
156	Real-world effectiveness evaluation of budesonide/formoterol Spiromax for the management of asthma and chronic obstructive pulmonary disease in the UK. BMJ Open, 2018, 8, e022051.	0.8	3
157	Adverse outcomes from initiation of systemic corticosteroids for asthma: long-term observational study. Journal of Asthma and Allergy, 2018, Volume 11, 193-204.	1.5	270
158	Exogenous sex steroid hormones and asthma in females: protocol for a population-based retrospective cohort study using a UK primary care database. BMJ Open, 2018, 8, e020075.	0.8	7
159	Performance of database-derived severe exacerbations and asthma control measures in asthma: responsiveness and predictive utility in a UK primary care database with linked questionnaire data. Journal of Pragmatic and Observational Research, 2018, Volume 9, 29-42.	1.1	18
160	Factors associated with appropriate inhaler use in patients with COPD – lessons from the REAL survey. International Journal of COPD, 2018, Volume 13, 695-702.	0.9	63
161	Real-life treatment of rhinitis in Australia: a historical cohort study of prescription and over-the-counter therapies for patients with and without additional respiratory disease. Journal of Pragmatic and Observational Research, 2018, Volume 9, 43-54.	1.1	6
162	Trends of testing for and diagnosis of α ₁ -antitrypsin deficiency in the UK: moreÂtesting is needed. European Respiratory Journal, 2018, 52, 1800360.	3.1	22

#	Article	IF	CITATIONS
163	Matching Inhaler Devices with Patients: The Role of the Primary Care Physician. Canadian Respiratory Journal, 2018, 2018, 1-9.	0.8	53
164	Evaluation of inhaler technique and achievement and maintenance of mastery of budesonide/formoterol Spiromax® compared with budesonide/formoterol Turbuhaler® in adult patients with asthma: the Easy Low Instruction Over Time (ELIOT) study. BMC Pulmonary Medicine, 2018, 18, 107.	0.8	9
165	The allergic allergist behaves like a patient. Annals of Allergy, Asthma and Immunology, 2018, 121, 741-742.	0.5	18
166	Applying UK real-world primary care data to predict asthma attacks in 3776 well-characterised children: a retrospective cohort study. Npj Primary Care Respiratory Medicine, 2018, 28, 28.	1.1	19
167	Association between blood eosinophil count and risk of readmission for patients with asthma: Historical cohort study. PLoS ONE, 2018, 13, e0201143.	1.1	28
168	Electronic Clinical Decision Support System for allergic rhinitis management: MASK e DSS. Clinical and Experimental Allergy, 2018, 48, 1640-1653.	1.4	61
169	Rhinology Future Debates 2017 by <scp>EUFOREA</scp> : Novel treatments and surgical solutions in rhinology. Clinical Otolaryngology, 2018, 43, 1429-1438.	0.6	3
170	Is the EQ-5D fit for purpose in asthma? Acceptability and content validity from the patient perspective. Health and Quality of Life Outcomes, 2018, 16, 160.	1.0	24
171	Real-life effectiveness and safety of salbutamol Steri-Nebâ,,¢ vs. Ventolin Nebules® for exacerbations in patients with COPD: Historical cohort study. PLoS ONE, 2018, 13, e0191404.	1.1	2
172	Osteoporosis onset in patients prescribed ICS for COPD: matched cohort study. , 2018, , .		1
173	Temporarily quadrupling the dose of inhaled steroid to prevent asthma exacerbations: FAST. Health Technology Assessment, 2018, 22, 1-82.	1.3	4
174	Late Breaking Abstract - Comparative real world effectiveness of triple therapy versus dual bronchodilation in frequently exacerbating patients with COPD. , 2018, , .		0
175	Late Breaking Abstract - Characteristics and treatment of patients with comorbid COPD and heart failure. , 2018, , .		Ο
176	Association between ICS therapy for COPD and diabetes onset and progression. , 2018, , .		0
177	Frequency of cough versus dyspnoea as the first recorded symptom of idiopathic pulmonary fibrosis. , 2018, , .		1
178	Prevalence of comorbidities in established and newly treated patients with COPD according to GOLD 2017 in a UK primary care population. , 2018, , .		0
179	Dual bronchodilation in COPD: lung function and patient-reported outcomes – a review. International Journal of COPD, 2017, Volume 12, 141-168.	0.9	26
180	The use of multiple respiratory inhalers requiring different inhalation techniques has an adverse effect on COPD outcomes. International Journal of COPD, 2017, Volume 12, 59-71.	0.9	90

#	Article	IF	CITATIONS
181	Real-Life Outcomes for Patients with Asthma Prescribed Spacers for Use with Either Extrafine- or Fine-Particle Inhaled Corticosteroids. Journal of Allergy and Clinical Immunology: in Practice, 2017, 5, 1040-1049.e4.	2.0	13
182	Pilot study of mobile phone technology in allergic rhinitis in European countries: the <scp>MASK</scp> â€rhinitis study. Allergy: European Journal of Allergy and Clinical Immunology, 2017, 72, 857-865.	2.7	93
183	Urinary prostanoids in preschool wheeze. European Respiratory Journal, 2017, 49, 1601390.	3.1	1
184	The impact of poor asthma control among asthma patients treated with inhaled corticosteroids plus long-acting β2-agonists in the United Kingdom: a cross-sectional analysis. Npj Primary Care Respiratory Medicine, 2017, 27, 17.	1.1	64
185	Work productivity in rhinitis using cell phones: The <scp>MASK</scp> pilot study. Allergy: European Journal of Allergy and Clinical Immunology, 2017, 72, 1475-1484.	2.7	69
186	Multicentre, non-interventional study to assess the profile of patients with uncontrolled rhinitis prescribed a novel formulation of azelastine hydrochloride and fluticasone propionate in a single spray in routine clinical practice in the UK. BMJ Open, 2017, 7, e014777.	0.8	5
187	Managing asthma in the era of biological therapies. Lancet Respiratory Medicine, the, 2017, 5, 376-378.	5.2	14
188	Use of electronic medical records and biomarkers to manage risk and resource efficiencies. European Clinical Respiratory Journal, 2017, 4, 1293386.	0.7	8
189	Allergic Rhinitis and its Impact on Asthma (ARIA) guidelines—2016 revision. Journal of Allergy and Clinical Immunology, 2017, 140, 950-958.	1.5	1,199
190	Urging Europe to put non-adherence to inhaled respiratory medication higher on the policy agenda: a report from the First European Congress on Adherence to Therapy. European Respiratory Journal, 2017, 49, 1700076.	3.1	33
191	Personalising care of adults with asthma from Asia: a modified e-Delphi consensus study to inform management tailored to attitude and control profiles. Npj Primary Care Respiratory Medicine, 2017, 27, 16089.	1.1	8
192	Comparative Effectiveness of Step-up Therapies in Children with Asthma Prescribed Inhaled Corticosteroids: A Historical Cohort Study. Journal of Allergy and Clinical Immunology: in Practice, 2017, 5, 1082-1090.e7.	2.0	7
193	A Randomized Pragmatic Trial of Changing to and Stepping Down Fluticasone/Formoterol in Asthma. Journal of Allergy and Clinical Immunology: in Practice, 2017, 5, 1378-1387.e5.	2.0	27
194	Inhaler Errors in the CRITIKAL Study: Type, Frequency, and Association with Asthma Outcomes. Journal of Allergy and Clinical Immunology: in Practice, 2017, 5, 1071-1081.e9.	2.0	229
195	Identifying Risk of Future Asthma Attacks Using UK Medical Record Data: A Respiratory Effectiveness Group Initiative. Journal of Allergy and Clinical Immunology: in Practice, 2017, 5, 1015-1024.e8.	2.0	82
196	Oral Corticosteroids Increase Risks of Onset of Diabetes Mellitus and Osteoporosis in a UK Patient Population. Chest, 2017, 152, A14.	0.4	2
197	Blood eosinophil count and exacerbation risk in patients with COPD. European Respiratory Journal, 2017, 50, 1700761.	3.1	64
198	Reply. Journal of Allergy and Clinical Immunology: in Practice, 2017, 5, 1163-1164.	2.0	0

#	Article	IF	CITATIONS
199	Validating the Concept of COPD Control: A Real-world Cohort Study from the United Kingdom. COPD: Journal of Chronic Obstructive Pulmonary Disease, 2017, 14, 504-512.	0.7	26
200	Fgf8 morphogen gradients are differentially regulated by heparan sulphotransferases Hs2st and Hs6st1 in the developing brain. Biology Open, 2017, 6, 1933-1942.	0.6	12
201	Modelling the effect of beliefs about asthma medication and treatment intrusiveness on adherence and preference for once-daily vs. twice-daily medication. Npj Primary Care Respiratory Medicine, 2017, 27, 61.	1.1	16
202	Redefining Cut-Points for High Symptom Burden of the Global Initiative for Chronic Obstructive Lung Disease Classification in 18,577 Patients With Chronic Obstructive Pulmonary Disease. Journal of the American Medical Directors Association, 2017, 18, 1097.e11-1097.e24.	1.2	38
203	Initiating or changing to a fixed-dose combination of Fluticasone propionate/Formoterol over Fluticasone propionate/Salmeterol: A real-life effectiveness and cost impact evaluation. Respiratory Medicine, 2017, 129, 199-206.	1.3	8
204	Ipratropium/Salbutamol Comparator Versus Originator for Chronic Obstructive Pulmonary Disease Exacerbations: USA Observational Cohort Study Using the Clinformaticsâ,,¢ Health Claims Database. Pulmonary Therapy, 2017, 3, 187-205.	1.1	0
205	Cohort Analysis of Exacerbation Rates in Adolescent and Adult Patients Initiating Inhaled Corticosteroids for Asthma: Different Dose–Response Profile by Particle Size. Pulmonary Therapy, 2017, 3, 113-124.	1.1	ο
206	The cost of systemic corticosteroid-induced morbidity in severe asthma: a health economic analysis. Respiratory Research, 2017, 18, 129.	1.4	57
207	Inhaled Corticosteroid Adherence Patterns in a Longitudinal Asthma Cohort. Journal of Allergy and Clinical Immunology: in Practice, 2017, 5, 448-456.e2.	2.0	20
208	Building bridges for innovation in ageing: Synergies between action groups of the EIP on AHA. Journal of Nutrition, Health and Aging, 2017, 21, 92-104.	1.5	47
209	Long-Acting β-Agonist in Combination or Separate Inhaler as Step-Up Therapy for Children with Uncontrolled Asthma Receiving Inhaled Corticosteroids. Journal of Allergy and Clinical Immunology: in Practice, 2017, 5, 99-106.e3.	2.0	15
210	The effect of smoking on exacerbation risk in eosinophilic patients with COPD. European Respiratory Journal, 2017, 50, 1702086.	3.1	0
211	CHRODIS criteria applied to the MASK (MACVIA-ARIA Sentinel NetworK) Good Practice in allergic rhinitis: a SUNFRAIL report. Clinical and Translational Allergy, 2017, 7, 37.	1.4	36
212	Cardiovascular risks in smokers treated with nicotine replacement therapy: a historical cohort study. Clinical Epidemiology, 2017, Volume 9, 231-243.	1.5	16
213	Seasonal patterns of oral antihistamine and intranasal corticosteroid purchases from Australian community pharmacies: a retrospective observational study. Journal of Pragmatic and Observational Research, 2017, Volume 8, 157-165.	1.1	5
214	The comparative effectiveness of initiating fluticasone/salmeterol combination therapy via pMDI versus DPI in reducing exacerbations and treatment escalation in COPD: a UK database study. International Journal of COPD, 2017, Volume 12, 2445-2454.	0.9	13
215	LABA/LAMA combinations versus LAMA monotherapy or LABA/ICS in COPD: a systematic review and meta-analysis. International Journal of COPD, 2017, Volume 12, 907-922.	0.9	109
216	Asthma referrals: a key component of asthma management that needs to be addressed. Journal of Asthma and Allergy, 2017, Volume10, 209-223.	1.5	61

#	Article	IF	CITATIONS
217	Effective deployment of technology-supported management of chronic respiratory conditions: a call for stakeholder engagement. Journal of Pragmatic and Observational Research, 2017, Volume 8, 119-128.	1.1	3
218	Real-life effectiveness and safety of the inhalation suspension budesonide comparator vs the originator product for the treatment of patients with asthma: a historical cohort study using a US health claims database. Journal of Pragmatic and Observational Research, 2017, Volume 8, 69-83.	1.1	2
219	Medication-related costs of rhinitis in Australia: a NostraData cross-sectional study of pharmacy purchases. Journal of Asthma and Allergy, 2017, Volume10, 153-161.	1.5	14
220	Risk of pneumonia in obstructive lung disease: A real-life study comparing extra-fine and fine-particle inhaled corticosteroids. PLoS ONE, 2017, 12, e0178112.	1.1	31
221	Identifying the hidden burden of allergic rhinitis (AR) in community pharmacy: a global phenomenon. Asthma Research and Practice, 2017, 3, 8.	1.2	41
222	An evaluation of exact matching and propensity score methods as applied in a comparative effectiveness study of inhaled corticosteroids in asthma. Journal of Pragmatic and Observational Research, 2017, Volume 8, 15-30.	1.1	43
223	Does co-payment for inhaler devices affect therapy adherence and disease outcomes? A historical, matched cohort study. Journal of Pragmatic and Observational Research, 2017, Volume 8, 31-41.	1.1	3
224	The effect of DPP-4 inhibitors on asthma control: an administrative database study to evaluate a potential pathophysiological relationship. Journal of Pragmatic and Observational Research, 2017, Volume 8, 231-240.	1.1	16
225	Asthma-Related Outcomes in Patients Initiating Extrafine Ciclesonide or Fine-Particle Inhaled Corticosteroids. Allergy, Asthma and Immunology Research, 2017, 9, 116.	1.1	11
226	Development and Validation of an Attitudinal-Profiling Tool for Patients With Asthma. Allergy, Asthma and Immunology Research, 2017, 9, 43.	1.1	10
227	A randomised controlled study of the effectiveness of breathing retraining exercises taught by a physiotherapist either by instructional DVD or in face-to-face sessions in the management of asthma in adults. Health Technology Assessment, 2017, 21, 1-162.	1.3	13
228	Breathing exercises for asthma - results of the BREATHE study. , 2017, , .		0
229	Comparative effectiveness of therapies for preschool children with recurrent wheezing. , 2017, , .		0
230	Association between blood eosinophil count and exacerbation risk in patients with asthma receiving medium- or high-dosage inhaled corticosteroids. , 2017, , .		0
231	Real-life evaluation of budesonide/formoterol (DuoResp Spiromax) for the management of asthma and COPD in the UK. , 2017, , .		Ο
232	Comparing asthma and COPD inhaler devices in real life clinical practice in the UK: differences in training requirements and preference. , 2017, , .		0
233	Association between blood eosinophil count and risk of exacerbations in patients with COPD. , 2017, , .		0
234	Association between blood eosinophil counts and risk of rehospitalization in patients with asthma. , 2017, , .		0

#	Article	IF	CITATIONS
235	Estimating exacerbation rates from routine UK primary care data: an exploratory validation from the IMP2ART programme. , 2017, , .		2
236	Late Breaking Abstract - Can a self-management plan, which includes a four-fold increase in inhaled corticosteroid dose, reduce severe asthma exacerbations: a randomised, pragmatic trial. , 2017, , .		1
237	Historical cohort study examining comparative effectiveness of albuterol inhalers with and without integrated dose counter for patients with asthma or chronic obstructive pulmonary disease. Journal of Asthma and Allergy, 2016, Volume 9, 145-154.	1.5	59
238	Impacts of coexisting bronchial asthma on severe exacerbations in mild-to-moderate COPD: results from a national database. International Journal of COPD, 2016, 11, 775.	0.9	8
239	2016 Respiratory Effectiveness Group Annual Summit Report—impact & influence of real-world respiratory evidence. Journal of Thoracic Disease, 2016, 8, S435-S444.	0.6	0
240	Predicting frequent asthma exacerbations using blood eosinophil count and other patient data routinely available in clinical practice. Journal of Asthma and Allergy, 2016, 9, 1.	1.5	114
241	Determinants and impact of suboptimal asthma control in Europe: The INTERNATIONAL CROSS-SECTIONAL AND LONGITUDINAL ASSESSMENT ON ASTHMA CONTROL (LIAISON) study. Respiratory Research, 2016, 17, 51.	1.4	110
242	First maintenance therapy for COPD in the UK between 2009 and 2012: a retrospective database analysis. Npj Primary Care Respiratory Medicine, 2016, 26, 16061.	1.1	20
243	Underuse of β-blockers in heart failure and chronic obstructive pulmonary disease. Heart, 2016, 102, 1909-1914.	1.2	65
244	lt is important to distinguish between HFrEF and HFpEF when interpreting these data. Heart, 2016, 102, 1934.1-1934.	1.2	3
245	Eligibility of real-life patients with COPD for inclusion in trials of inhaled long-acting bronchodilator therapy. Respiratory Research, 2016, 17, 120.	1.4	45
246	Allergy immunotherapy across the life cycle to promote active and healthy ageing: from research to policies. Clinical and Translational Allergy, 2016, 6, 41.	1.4	24
247	Lessons learnt from a primary care asthma improvement project. Npj Primary Care Respiratory Medicine, 2016, 26, 15075.	1.1	7
248	ARIA 2016: Care pathways implementing emerging technologies for predictive medicine in rhinitis and asthma across the life cycle. Clinical and Translational Allergy, 2016, 6, 47.	1.4	121
249	Asthma-specific health-related quality of life of people in Great Britain: A national survey. Journal of Asthma, 2016, 53, 975-982.	0.9	12
250	MACVIA clinical decision algorithm in adolescents and adults with allergic rhinitis. Journal of Allergy and Clinical Immunology, 2016, 138, 367-374.e2.	1.5	128
251	The Relationship Between 24-Hour Symptoms and COPD Exacerbations and Healthcare Resource Use: Results from an Observational Study (ASSESS). COPD: Journal of Chronic Obstructive Pulmonary Disease, 2016, 13, 561-568.	0.7	17
252	Asthma in Asia: Physician perspectives on control, inhaler use and patient communications. Journal of Asthma, 2016, 53, 761-769.	0.9	19

#	Article	IF	CITATIONS
253	"Trying, But Failing―— The Role of Inhaler Technique and Mode of Delivery in Respiratory Medication Adherence. Journal of Allergy and Clinical Immunology: in Practice, 2016, 4, 823-832.	2.0	92
254	What We Mean When We Talk About Adherence in Respiratory Medicine. Journal of Allergy and Clinical Immunology: in Practice, 2016, 4, 802-812.	2.0	104
255	A New Digital Tool to Assess Allergic Rhinitis Symptom Control. Journal of Allergy and Clinical Immunology, 2016, 137, AB95.	1.5	1
256	Respiratory Medication Adherence: Toward a Common Language and a Shared Vision. Journal of Allergy and Clinical Immunology: in Practice, 2016, 4, 799-801.	2.0	7
257	A practical tool for primary care antimicrobial stewardship in children. Lancet Respiratory Medicine,the, 2016, 4, 850-852.	5.2	0
258	COPD case finding: effective, but also cost-effective?. Lancet Respiratory Medicine,the, 2016, 4, e49.	5.2	3
259	Incidence of oral thrush in patients with COPD prescribed inhaled corticosteroids: Effect of drug, dose, and device. Respiratory Medicine, 2016, 120, 54-63.	1.3	35
260	MP-AzeFlu provides rapid and effective allergic rhinitis control in real life: A pan-European study. Allergy and Asthma Proceedings, 2016, 37, 376-386.	1.0	25
261	Scaling up strategies of the chronic respiratory disease programme of the European Innovation Partnership on Active and Healthy Ageing (Action Plan B3: Area 5). Clinical and Translational Allergy, 2016, 6, 29.	1.4	47
262	Cost Effectiveness of the Long-Acting 1 ² 2-Adrenergic Agonist (LABA)/Long-Acting Muscarinic Antagonist Dual Bronchodilator Indacaterol/Glycopyrronium Versus the LABA/Inhaled Corticosteroid Combination Salmeterol/Fluticasone in Patients with Chronic Obstructive Pulmonary Disease: Analyses Conducted for Canada, France, Italy, and Portugal. Applied Health Economics and Health	1.0	12
263	Policy, 2016, 14, 579-594. The prevalence of comorbidities in COPD patients, and their impact on health status and COPD symptoms in primary care patients: a protocol for an UNLOCK study from the IPCRG. Npj Primary Care Respiratory Medicine, 2016, 26, 16069.	1.1	4
264	FourFold Asthma Study (FAST): a study protocol for a randomised controlled trial evaluating the clinical cost-effectiveness of temporarily quadrupling the dose of inhaled steroid to prevent asthma exacerbations. Trials, 2016, 17, 499.	0.7	4
265	Changes in initial COPD treatment choice over time and factors influencing prescribing decisions in UK primary care: a real-world study. Npj Primary Care Respiratory Medicine, 2016, 26, 16002.	1.1	37
266	Multi-component assessment of chronic obstructive pulmonary disease: an evaluation of the ADO and DOSE indices and the global obstructive lung disease categories in international primary care data sets. Npj Primary Care Respiratory Medicine, 2016, 26, 16010.	1.1	22
267	Are pharmacological randomised controlled clinical trials relevant to real-life asthma populations? A protocol for an UNLOCK study from the IPCRG. Npj Primary Care Respiratory Medicine, 2016, 26, 16016.	1.1	6
268	UK prescribing practices as proxy markers of unmet need in allergic rhinitis: a retrospective observational study. Npj Primary Care Respiratory Medicine, 2016, 26, 16033.	1.1	17
269	Inappropriate asthma therapy—a tale of two countries: a parallel population-based cohort study. Npj Primary Care Respiratory Medicine, 2016, 26, 16076.	1.1	28
270	Cost comparison of asthma treatments in 12-week study: caution about matching and short observational follow-up. Multidisciplinary Respiratory Medicine, 2016, 11, 39.	0.6	0

#	Article	IF	CITATIONS
271	What is asthmaâ^'COPD overlap syndrome? Towards a consensus definition from a round table discussion. European Respiratory Journal, 2016, 48, 664-673.	3.1	287
272	Cost-Effectiveness of Asthma Step-Up Therapy as an Increased Dose of Extrafine-Particle Inhaled Corticosteroid or Add-On Long-Acting Beta2-Agonist. Pulmonary Therapy, 2016, 2, 73-89.	1.1	1
273	Reply. Journal of Allergy and Clinical Immunology: in Practice, 2016, 4, 372-373.	2.0	0
274	Comparison of serious inhaler technique errors made by device-naÃ⁻ve patients using three different dry powder inhalers: a randomised, crossover, open-label study. BMC Pulmonary Medicine, 2016, 16, 12.	0.8	28
275	Insights, attitudes, and perceptions about asthma and its treatment: a multinational survey of patients from Europe and Canada. World Allergy Organization Journal, 2016, 9, 13.	1.6	41
276	Add-on LABA in a separate inhaler as asthma step-up therapy <i>versus</i> increased dose of ICS or ICS/LABA combination inhaler. ERJ Open Research, 2016, 2, 00106-2015.	1.1	11
277	Effectiveness of initiating extrafine-particle versus fine-particle inhaled corticosteroids as asthma therapy in the Netherlands. BMC Pulmonary Medicine, 2016, 16, 80.	0.8	15
278	Inhaled corticosteroid dose-response on blood eosinophils in asthma – Authors' reply. Lancet Respiratory Medicine,the, 2016, 4, e1-e2.	5.2	1
279	Comorbidity in severe asthma requiring systemic corticosteroid therapy: cross-sectional data from the Optimum Patient Care Research Database and the British Thoracic Difficult Asthma Registry. Thorax, 2016, 71, 339-346.	2.7	257
280	Effectiveness of allergic rhinitis treatments in real-life with a focus on MP-AzeFlu. Expert Review of Clinical Pharmacology, 2016, 9, 705-714.	1.3	1
281	Characteristics of patients making serious inhaler errors with a dry powder inhaler and association with asthma-related events in a primary care setting. Journal of Asthma, 2016, 53, 321-329.	0.9	86
282	Safety evaluation of MP29-02 (a novel intranasal formulation of azelastine hydrochloride and) Tj ETQq0 0 0 rgBT	/Overlock	10 Tf 50 30
283	IgE-mediated asthma: New revelations and future insights. Respiratory Medicine, 2016, 112, 128-129.	1.3	18
284	Metabolic Effects Associated with ICS in Patients with COPD and Comorbid Type 2 Diabetes: A Historical Matched Cohort Study. PLoS ONE, 2016, 11, e0162903.	1.1	43
285	Time to get real: critical and imperative change required in evidence evaluation. Journal of Thoracic Disease, 2016, 8, S431-S434.	0.6	2
286	AB012. Current burden of uncontrolled asthma in the general population: the OPCRD asthma state of the Union study. Journal of Thoracic Disease, 2016, 8, AB012-AB012.	0.6	1
287	Current burden of uncontrolled asthma in the general population: The OPCRD asthma state of the union study. , 2016, , .		0
288	Effect of ICS on glycaemic control in patients with COPD and comorbid type 2 diabetes: Historical case-matched cohort study. , 2016, , .		0

#	Article	IF	CITATIONS
289	Real-life effectiveness of budesonide/formoterol for the management of asthma and COPD. , 2016, , .		0
290	Validation of the COPD control concept: A UK pilot. , 2016, , .		0
291	Inappropriate asthma therapy: A tale of two countries. , 2016, , .		0
292	The role of adherence to inhaled corticosteroids (ICS) in the relationship between blood eosinophilia and asthma control. , 2016, , .		0
293	Adherence to asthma medication and preferences for once-daily treatment: Importance of treatment intrusiveness and patient beliefs. , 2016, , .		0
294	The prevalence of comorbidities in COPD patients and their impact on quality of life and COPD symptoms in primary care patients - An UNLOCK study from the IPCRG. , 2016, , .		1
295	MACVIA-ARIA Sentinel NetworK for allergic rhinitis (MASK-rhinitis): the new generation guideline implementation. Allergy: European Journal of Allergy and Clinical Immunology, 2015, 70, 1372-1392.	2.7	160
296	How to match the optimal currently available inhaler device to an individual child with asthma or recurrent wheeze. Npj Primary Care Respiratory Medicine, 2015, 25, 14088.	1.1	21
297	Initial step-up treatment changes in asthmatic children already prescribed inhaled corticosteroids: a historical cohort study. Npj Primary Care Respiratory Medicine, 2015, 25, 15041.	1.1	9
298	The hidden burden of adult allergic rhinitis: UK healthcare resource utilisation survey. Clinical and Translational Allergy, 2015, 5, 39.	1.4	82
299	A common language to assess allergic rhinitis control: results from a survey conducted during EAACI 2013 Congress. Clinical and Translational Allergy, 2015, 5, 36.	1.4	23
300	Use of low-dose oral theophylline as an adjunct to inhaled corticosteroids in preventing exacerbations of chronic obstructive pulmonary disease: study protocol for a randomised controlled trial. Trials, 2015, 16, 267.	0.7	20
301	Concept review of dry powder inhalers: correct interpretation of published data. Multidisciplinary Respiratory Medicine, 2015, 10, 36.	0.6	3
302	Establishing the relationship of inhaler satisfaction, treatment adherence, and patient outcomes: a prospective, real-world, cross-sectional survey of US adult asthma patients and physicians. World Allergy Organization Journal, 2015, 8, 26.	1.6	52
303	Effectiveness of MP29-02 for the treatment of allergic rhinitis in real-life: Results from a noninterventional study. Allergy and Asthma Proceedings, 2015, 36, 40-47.	1.0	49
304	Predicting frequent COPD exacerbations using primary care data. International Journal of COPD, 2015, 10, 2439.	0.9	48
305	Comorbidities of patients in tiotropium clinical trials: comparison with observational studies of patients with chronic obstructive pulmonary disease. International Journal of COPD, 2015, 10, 549.	0.9	26
306	Physician-prescribed Asthma Treatment Regimen does not differ Between Smoking and Non-smoking Patients With Asthma in Seoul and Gyunggi province of Korea. Allergy, Asthma and Immunology Research, 2015, 7, 30.	1.1	1

#	Article	IF	CITATIONS
307	Delivering a drug study in primary care: trial management challenges and solutions. Trials, 2015, 16, .	0.7	0
308	The inevitable drift to triple therapy in COPD: an analysis of prescribing pathways in the UK. International Journal of COPD, 2015, 10, 2207.	0.9	85
309	Time for a new language for asthma control: results from REALISE Asia. Journal of Asthma and Allergy, 2015, 8, 93.	1.5	51
310	Long-acting muscarinic antagonist use in adults with asthma: real-life prescribing and outcomes of add-on therapy with tiotropium bromide. Journal of Asthma and Allergy, 2015, 8, 1.	1.5	29
311	Patient Reported Burden of Asthma on Resource Use and Productivity Across 11 Countries in Europe. Advances in Therapy, 2015, 32, 370-380.	1.3	11
312	Increased Dose of Inhaled Corticosteroid versus Add-On Long-acting β-Agonist for Step-Up Therapy in Asthma. Annals of the American Thoracic Society, 2015, 12, 798-806.	1.5	19
313	Efficacy of fluticasone propionate/formoterol fumarate in the treatment of asthma: A pooled analysis. Respiratory Medicine, 2015, 109, 208-217.	1.3	8
314	Advances in pharmacotherapy for the treatment of allergic rhinitis; MP29-02 (a novel formulation of) Tj ETQq0 (Expert Opinion on Pharmacotherapy, 2015, 16, 913-928.	0 0 rgBT /C 0.9	Overlock 10 T 28
315	A re-evaluation of the role of inhaled corticosteroids in the management of patients with chronic obstructive pulmonary disease. Expert Opinion on Pharmacotherapy, 2015, 16, 1845-1860.	0.9	30
316	Small-particle Inhaled Corticosteroid as First-line or Step-up Controller Therapy in Childhood Asthma. Journal of Allergy and Clinical Immunology: in Practice, 2015, 3, 721-731.e16.	2.0	38
317	Taking Aim at Asthma Around the World: Global Results ofÂthe Asthma Insight and Management Survey in the Asia-Pacific Region, Latin America, Europe, Canada, andÂthe United States. Journal of Allergy and Clinical Immunology: in Practice, 2015, 3, 734-742.e5.	2.0	67
318	Differential Effects of Inhaled Corticosteroids in Smokers/Ex-Smokers and Nonsmokers with Asthma. American Journal of Respiratory and Critical Care Medicine, 2015, 191, 960-964.	2.5	23
319	Monitoring asthma in children. European Respiratory Journal, 2015, 45, 906-925.	3.1	114
320	Assessing the clinical value of fast onset and sustained duration of action of long-acting bronchodilators for COPD. Pulmonary Pharmacology and Therapeutics, 2015, 31, 68-78.	1.1	36
321	Blood eosinophil count and prospective annual asthma disease burden: a UK cohort study. Lancet Respiratory Medicine,the, 2015, 3, 849-858.	5.2	443
322	Cost-Effectiveness of Glycopyrronium Bromide Compared with Tiotropium in Patients with Chronic Obstructive Pulmonary Disease in Sweden. Applied Health Economics and Health Policy, 2015, 13, 637-645.	1.0	9
323	Monitoring asthma in childhood: symptoms, exacerbations and quality of life. European Respiratory Review, 2015, 24, 187-193.	3.0	40
324	Real-world research and its importance in respiratory medicine. Breathe, 2015, 11, 26-38.	0.6	66

#	Article	IF	CITATIONS
325	Current controversies and challenges in allergic rhinitis management. Expert Review of Clinical Immunology, 2015, 11, 1205-1217.	1.3	31
326	Dual bronchodilator therapy with aclidinium bromide/formoterol fumarate for chronic obstructive pulmonary disease. Expert Review of Respiratory Medicine, 2015, 9, 519-532.	1.0	6
327	QVA149 compared with salmeterol/fluticasone (SFC) on exacerbations and its correlation with baseline blood eosinophils: A pooled analysis of LANTERN and ILLUMINATE. , 2015, , .		4
328	REG study: Real-life, longitudinal ICS adherence patterns in a UK asthma population. , 2015, , .		1
329	Eligibility of patients with COPD for inclusion in trials of inhaled long-acting bronchodilator therapy. , 2015, , .		Ο
330	Predicting asthma exacerbations in children $\hat{a} \in \hat{A}$ real life observational study. , 2015, , .		0
331	Prescribed doses and effect on asthma treatment outcomes of extrafine (ciclesonide) vs standard particle inhaled corticosteroids (ICS). , 2015, , .		Ο
332	Asthma severity, poor control, co-morbidities and prior resource use determined omalizumab prescriptions in a nested case-control study with US claims data. , 2015, , .		0
333	Respiratory effectiveness group study: Predictors of frequent severe asthma exacerbations. , 2015, , .		0
334	Prevalence of serious post-training inhaler technique errors made by device-naÃ ⁻ ve patients using three different dry powder inhalers (DPIs). , 2015, , .		0
335	LATE-BREAKING ABSTRACT: One-year assessment of asthma control and quality of life in Europe: The liaison study (international cross-sectional and longitudinal assessment on asthma control). , 2015, , .		0
336	Dose-response effect of small particle vs standard size particle inhaled corticosteroids on severe asthma exacerbations by sex. , 2015, , .		0
337	Investigating inhaler device mastery in pharmacist trainees. , 2015, , .		1
338	Parent-determined oral montelukast therapy for preschool wheeze with stratification for arachidonate 5-lipoxygenase (ALOX5) promoter genotype: a multicentre, randomised, placebo-controlled trial. Efficacy and Mechanism Evaluation, 2015, 2, 1-126.	0.9	0
339	Adjunctive treatment with oral AKL1, a botanical nutraceutical, in chronic obstructive pulmonary disease. International Journal of COPD, 2014, 9, 715.	0.9	1
340	Switching patients from other inhaled corticosteroid devices to the Easyhaler®: historical, matched-cohort study of real-life asthma patients. Journal of Asthma and Allergy, 2014, 7, 31.	1.5	17
341	Management of COPD in the UK primary-care setting: an analysis of real-life prescribing patterns. International Journal of COPD, 2014, 9, 889.	0.9	210
342	Comparing the effectiveness of small-particle versus large-particle inhaled corticosteroid in COPD. International Journal of COPD, 2014, 9, 1163.	0.9	18

#	Article	IF	CITATIONS
343	Real-world characterization and differentiation of the Global Initiative for Chronic Obstructive Lung Disease strategy classification. International Journal of COPD, 2014, 9, 551.	0.9	35
344	Integrating Evidence for Managing Asthma in Patients Who Smoke. Allergy, Asthma and Immunology Research, 2014, 6, 114.	1.1	22
345	Quality Standards for Real-World Research. Focus on Observational Database Studies of Comparative Effectiveness. Annals of the American Thoracic Society, 2014, 11, S99-S104.	1.5	115
346	Types, frequency and impact of asthma triggers on patients' lives: a quantitative study in five European countries. Journal of Asthma, 2014, 51, 127-135.	0.9	20
347	Fluticasone propionate/formoterol fumarate in fixed-dose combination for the treatment of asthma. Expert Review of Respiratory Medicine, 2014, 8, 275-291.	1.0	3
348	The Arch Conference Declaration. Helping to Further the Science of Pragmatic Research. Annals of the American Thoracic Society, 2014, 11, S83-S84.	1.5	2
349	Complementing the Randomized Controlled Trial Evidence Base. Evolution Not Revolution. Annals of the American Thoracic Society, 2014, 11, S92-S98.	1.5	51
350	Cost-effectiveness of the LABA/LAMA dual bronchodilator indacaterol/glycopyrronium in a Swedish healthcare setting. Respiratory Medicine, 2014, 108, 1786-1793.	1.3	32
351	Detection of airflow limitation using a handheld spirometer in a primary care setting. Respirology, 2014, 19, 689-693.	1.3	19
352	Observational study to characterise 24-hour COPD symptoms and their relationship with patient-reported outcomes: results from the ASSESS study. Respiratory Research, 2014, 15, 122.	1.4	144
353	Current evidence and future research needs for FeNO measurement in respiratory diseases. Respiratory Medicine, 2014, 108, 830-841.	1.3	157
354	Opportunities to diagnose chronic obstructive pulmonary disease in routine care in the UK: a retrospective study of a clinical cohort. Lancet Respiratory Medicine,the, 2014, 2, 267-276.	5.2	149
355	Intermittent montelukast in children aged 10 months to 5 years with wheeze (WAIT trial): a multicentre, randomised, placebo-controlled trial. Lancet Respiratory Medicine,the, 2014, 2, 796-803.	5.2	72
356	Long-term, Randomized Safety Study of MP29-02 (a Novel Intranasal Formulation of Azelastine) Tj ETQq0 0 0 rgB1 Rhinitis. Journal of Allergy and Clinical Immunology: in Practice, 2014, 2, 179-185.	[/Overlock 2.0	k 10 Tf 50 2 50
357	Allergic Rhinitis (AR) Is Sub-Optimally Controlled: The Need For a More Effective Treatment Option. Journal of Allergy and Clinical Immunology, 2014, 133, AB132.	1.5	0
358	Integrated care pathways for airway diseases (AIRWAYS-ICPs). European Respiratory Journal, 2014, 44, 304-323.	3.1	154
359	Interstitial lung disease: raising the index of suspicion in primary care. Npj Primary Care Respiratory Medicine, 2014, 24, 14054.	1.1	15
360	Is there a rationale and role for long-acting anticholinergic bronchodilators in asthma?. Npj Primary Care Respiratory Medicine, 2014, 24, 14023.	1.1	36

#	Article	IF	CITATIONS
361	Asthma control and management in 8,000 European patients: the REcognise Asthma and LInk to Symptoms and Experience (REALISE) survey. Npj Primary Care Respiratory Medicine, 2014, 24, 14009.	1.1	453
362	Cost-effectiveness of initiating extrafine- or standard size-particle inhaled corticosteroid for asthma in two health-care systems: a retrospective matched cohort study. Npj Primary Care Respiratory Medicine, 2014, 24, 14081.	1.1	21
363	S91 Once-daily tiotropium Respimat(R) add-on to ICS + LABA improves symptom control and reduces exacerbations in patients with symptomatic asthma. Thorax, 2014, 69, A49-A50.	2.7	1
364	Exploring the role of quantitative feedback in inhaler technique education: a cluster-randomised, two-arm, parallel-group, repeated-measures study. Npj Primary Care Respiratory Medicine, 2014, 24, 14071.	1.1	29
365	S92 Efficacy Of Once-daily Tiotropium Respimat(R) 5 Âg From Five Phase lii Trials In Adults With Symptomatic Asthma. Thorax, 2014, 69, A50-A50.	2.7	1
366	Systems Medicine Approaches for the Definition of Complex Phenotypes in Chronic Diseases and Ageing. From Concept to Implementation and Policies. Current Pharmaceutical Design, 2014, 20, 5928-5944.	0.9	63
367	A new therapy (MP29â€02*) effectively controls nasal symptoms of seasonal allergic rhinitis irrespective of severity. Clinical and Translational Allergy, 2013, 3, O16.	1.4	0
368	A new therapy (MP29â $\in 02^*$) effectively treats patients with seasonal allergic rhinitis who suffer most from the bothersome nasal symptom of congestion. Clinical and Translational Allergy, 2013, 3, P39.	1.4	0
369	InternationaL cross-sectIonAl and longItudinal assessment on aSthma cONtrol in European adult patients - the LIAISON study protocol. BMC Pulmonary Medicine, 2013, 13, 18.	0.8	7
370	Improving Clinical Reality in Chronic Obstructive Pulmonary Disease Economic Modelling. Pharmacoeconomics, 2013, 31, 151-161.	1.7	23
371	A UK-Based Cost-Utility Analysis of Indacaterol, A Once-Daily Maintenance Bronchodilator for Patients with COPD, Using Real World Evidence on Resource Use. Applied Health Economics and Health Policy, 2013, 11, 259-274.	1.0	27
372	Prescription of inhalers in asthma and COPD: Towards a rational, rapid and effective approach. Respiratory Medicine, 2013, 107, 1817-1821.	1.3	87
373	Comparative Effectiveness of Extrafine Hydrofluoroalkane Beclometasone (EF HFA-BDP) and Fluticasone Propionate (FP) in Smoking Asthmatic Patients — a Retrospective, Real-Life Observational Study in a UK Primary Care Asthma Population. Journal of Allergy and Clinical Immunology, 2013, 131, AB3.	1.5	1
374	Asthma outcomes and costs of therapy with extrafine beclomethasone and fluticasone. Journal of Allergy and Clinical Immunology, 2013, 132, 45-54.e10.	1.5	55
375	The Role of Exhaled Nitric Oxide in Guiding Asthma Management. Journal of Allergy and Clinical Immunology, 2013, 131, AB205.	1.5	0
376	Real-life comparison of beclometasone dipropionate as an extrafine- or larger-particle formulation for asthma. Respiratory Medicine, 2013, 107, 987-1000.	1.3	40
377	Integrating real-life studies in the global therapeutic research framework. Lancet Respiratory Medicine,the, 2013, 1, e29-e30.	5.2	102
378	GOLD COPD categories are not fit for purpose in primary care. Lancet Respiratory Medicine,the, 2013, 1, e17.	5.2	16

#	Article	IF	CITATIONS
379	Effect of montelukast for treatment of asthma in cigarette smokers. Journal of Allergy and Clinical Immunology, 2013, 131, 763-771.e6.	1.5	58
380	Inhaler competence in asthma: Common errors, barriers to use and recommended solutions. Respiratory Medicine, 2013, 107, 37-46.	1.3	289
381	Using fractional exhaled nitric oxide (FeNO) to diagnose steroidâ€responsive disease and guide asthma management in routine care. Clinical and Translational Allergy, 2013, 3, 37.	1.4	46
382	Feasibility and Ethics. American Journal of Respiratory and Critical Care Medicine, 2013, 188, 1368-1369.	2.5	2
383	What we should learn from the London Olympics. Current Opinion in Allergy and Clinical Immunology, 2013, 13, 1-3.	1.1	9
384	A BOLD statement on how to case-find moderate/severe COPD. European Respiratory Journal, 2013, 41, 503-504.	3.1	8
385	Clinically Relevant Effect of a New Intranasal Therapy (MP29-02) in Allergic Rhinitis Assessed by Responder Analysis. International Archives of Allergy and Immunology, 2013, 161, 369-377.	0.9	104
386	Efficacy versus effectiveness trials. Current Opinion in Allergy and Clinical Immunology, 2013, 13, 50-57.	1.1	34
387	Challenges of COPD diagnosis. Expert Opinion on Medical Diagnostics, 2013, 7, 543-556.	1.6	11
388	The BREATHE study: Breathing REtraining for Asthma — Trial of Home Exercises. A protocol summary of a randomised controlled trial. Primary Care Respiratory Journal: Journal of the General Practice Airways Group, 2013, 22, PS1-PS7.	2.5	12
389	Characteristics of patients preferring once-daily controller therapy for asthma and COPD: a retrospective cohort study. Primary Care Respiratory Journal: Journal of the General Practice Airways Group, 2013, 22, 161-168.	2.5	37
390	Clinical and cost effectiveness of switching asthma patients from fluticasone-salmeterol to extra-fine particle beclometasone-formoterol: a retrospective matched observational study of real-world patients. Primary Care Respiratory Journal: Journal of the General Practice Airways Group, 2013, 22, 439-448.	2.5	39
391	Impact of night-time symptoms in COPD: a real-world study in five European countries. International Journal of COPD, 2013, 8, 595.	0.9	87
392	Management of Asthma in School age Children On Therapy (MASCOT): a randomised, double-blind, placebo-controlled, parallel study of efficacy and safety. Health Technology Assessment, 2013, 17, 1-218.	1.3	26
393	A new therapy (MP29-02) is effective for the long-term treatment of chronic rhinitis. Journal of Investigational Allergology and Clinical Immunology, 2013, 23, 495-503.	0.6	51
394	Prescribing and guidelines: both must improve to combat antimicrobial resistance. European Respiratory Journal, 2012, 39, 1050-1050.	3.1	0
395	MP29-02 (a novel intranasal formulation of azelastine hydrochloride and fluticasone propionate) in the treatment of seasonal allergic rhinitis: A randomized, double-blind, placebo-controlled trial of efficacy and safety. Allergy and Asthma Proceedings, 2012, 33, 324-332.	1.0	80
396	Clinical and cost effectiveness of mobile phone supported self monitoring of asthma: multicentre randomised controlled trial. BMJ: British Medical Journal, 2012, 344, e1756-e1756.	2.4	170

#	Article	IF	CITATIONS
397	Inhaled Corticosteroid/Long-Acting β ₂ -Agonist Combination Therapy for Asthma: Attitudes of Specialists in Europe. International Archives of Allergy and Immunology, 2012, 157, 303-310.	0.9	19
398	The at-risk registers in severe asthma (ARRISA) study: a cluster-randomised controlled trial examining effectiveness and costs in primary care. Thorax, 2012, 67, 1052-1060.	2.7	36
399	Asthma at-risk registers — can be effective if carefully constructed and correctly implemented. Primary Care Respiratory Journal: Journal of the General Practice Airways Group, 2012, 21, 135-136.	2.5	0
400	Spirometry: an essential tool for screening, case-finding, and diagnosis of COPD. Primary Care Respiratory Journal: Journal of the General Practice Airways Group, 2012, 21, 128-130.	2.5	24
401	Comparison of intranasal azelastine to intranasal fluticasone propionate for symptom control in moderate-to-severe seasonal allergic rhinitis. Allergy and Asthma Proceedings, 2012, 33, 450-458.	1.0	26
402	Clinical implications of the Royal College of Physicians three questions in routine asthma care: a real-life validation study. Primary Care Respiratory Journal: Journal of the General Practice Airways Group, 2012, 21, 288-294.	2.5	41
403	Risk-to-benefit ratio of inhaled corticosteroids in patients with COPD. Primary Care Respiratory Journal: Journal of the General Practice Airways Group, 2012, 22, 92-100.	2.5	148
404	PRS47 Analysis of New Prescriptions for Long-Acting β2-Agonists in Five European Countries in 2011. Value in Health, 2012, 15, A568.	0.1	1
405	A novel intranasal therapy of azelastine with fluticasone for the treatment of allergic rhinitis. Journal of Allergy and Clinical Immunology, 2012, 129, 1282-1289.e10.	1.5	212
406	Allergic Rhinitis and its Impact on Asthma (ARIA): Achievements in 10 years and future needs. Journal of Allergy and Clinical Immunology, 2012, 130, 1049-1062.	1.5	486
407	PMD92 Inhaler Use in Five European Countries: Analysis of Sales Data From Q4 2005 to Q4 2011. Value in Health, 2012, 15, A361.	0.1	2
408	Real-world perceptions of inhaled corticosteroid/long-acting β2-agonist combinations in the treatment of asthma. Respiratory Medicine, 2012, 106, S4-S8.	1.3	8
409	Severe Chronic Allergic (and Related) Diseases: A Uniform Approach – A MeDALL – GA ² LEN – ARIA Position Paper. International Archives of Allergy and Immunology, 2012, 158, 216-231.	0.9	83
410	The challenge of recruiting in primary care for a trial of telemonitoring in asthma: an observational study. Journal of Pragmatic and Observational Research, 2012, 3, 51.	1.1	5
411	Effectiveness of Same Versus Mixed Asthma Inhaler Devices: A Retrospective Observational Study in Primary Care. Allergy, Asthma and Immunology Research, 2012, 4, 184.	1.1	58
412	Practical guide to skin prick tests in allergy to aeroallergens. Allergy: European Journal of Allergy and Clinical Immunology, 2012, 67, 18-24.	2.7	475
413	International consensus on (ICON) pediatric asthma. Allergy: European Journal of Allergy and Clinical Immunology, 2012, 67, 976-997.	2.7	327
414	EPOS 2012: European position paper on rhinosinusitis and nasal polyps 2012. A summary for otorhinolaryngologists. Rhinology, 2012, 50, 1-12.	0.7	1,086

#	Article	IF	CITATIONS
415	EPOS 2012: European position paper on rhinosinusitis and nasal polyps 2012. A summary for otorhinolaryngologists. Rhinology, 2012, 50, 1-12.	0.7	1,665
416	Leukotriene Antagonists as First-Line or Add-on Asthma-Controller Therapy. New England Journal of Medicine, 2011, 364, 1695-1707.	13.9	231
417	New horizons in early stage COPD – Improving knowledge, detection and treatment. Respiratory Medicine, 2011, 105, 1576-1587.	1.3	42
418	Device type and real-world effectiveness of asthma combination therapy: An observational study. Respiratory Medicine, 2011, 105, 1457-1466.	1.3	64
419	Cost-utility analysis of indacaterol in Germany: A once-daily maintenance bronchodilator for patients with COPD. Respiratory Medicine, 2011, 105, 1635-1647.	1.3	34
420	Effectiveness of inhaler types for real-world asthma management: retrospective observational study using the GPRD. Journal of Asthma and Allergy, 2011, 4, 37.	1.5	39
421	Physicians' attitudes towards combination therapy with inhaled corticosteroids and long-acting ß2-agonists: an observational study in UK specialist care. Journal of Pragmatic and Observational Research, 2011, 2, 25.	1.1	2
422	Role of clinical questionnaires in optimizing everyday care of chronic obstructive pulmonary disease. International Journal of COPD, 2011, 6, 289.	0.9	37
423	Current Control and Future Risk in Asthma Management. Allergy, Asthma and Immunology Research, 2011, 3, 217.	1.1	56
424	The final frontier: The UK's new coalition government turns the English National Health Service over to the global health care market. Health Sociology Review, 2011, 20, 294-305.	1.7	26
425	The Asthma Control Test (ACT) as an alternative tool to Global Initiative for Asthma (GINA) guideline criteria for assessing asthma control in Vietnamese outpatients. Primary Care Respiratory Journal: Journal of the General Practice Airways Group, 2011, 21, 85-89.	2.5	43
426	Detecting mild COPD is not a waste of resources. Primary Care Respiratory Journal: Journal of the General Practice Airways Group, 2011, 20, 238-239.	2.5	5
427	From awareness to involvement? A qualitative study of respiratory patients' awareness of health service change. Health Expectations, 2011, 14, 321-333.	1.1	8
428	Asthma control with extrafineâ€particle hydrofluoroalkane–beclometasone vs. largeâ€particle chlorofluorocarbon–beclometasone: a realâ€world observational study. Clinical and Experimental Allergy, 2011, 41, 1521-1532.	1.4	59
429	Reassessing the Evidence Hierarchy in Asthma: Evaluating Comparative Effectiveness. Current Allergy and Asthma Reports, 2011, 11, 526-38.	2.4	41
430	Inhaler devices for asthma: a call for action in a neglected field. European Respiratory Journal, 2011, 37, 982-985.	3.1	86
431	Implementing the change in National Institute for Health and Clinical Excellence guidance on airflow obstruction grading in chronic obstructive pulmonary disease. Thorax, 2011, 66, 543-544.	2.7	0
432	Clinical trials and tribulations: the MASCOT study. Thorax, 2011, 66, 457-458.	2.7	17

#	Article	IF	CITATIONS
433	A pragmatic single-blind randomised controlled trial and economic evaluation of the use of leukotriene receptor antagonists in primary care at steps 2 and 3 of the national asthma guidelines (ELEVATE study) Health Technology Assessment, 2011, 15, 1-132.	1.3	15
434	A Survey on the Management of Acute Rhinosinusitis Among Asian Physicians. Rhinology, 2011, 49, 264-271.	0.7	45
435	Health Status Of COPD Patients In Clinical Practice In Three Countries In Europe. , 2010, , .		0
436	Setting the standard for routine asthma consultations: a discussion of the aims, process and outcomes of reviewing people with asthma in primary care. Primary Care Respiratory Journal: Journal of the General Practice Airways Group, 2010, 19, 75-83.	2.5	42
437	Earlier diagnosis and earlier treatment of COPD in primary care. Primary Care Respiratory Journal: Journal of the General Practice Airways Group, 2010, 20, 15-22.	2.5	73
438	UNLOCK: Uncovering and Noting Long-term Outcomes in COPD to enhance Knowledge. Primary Care Respiratory Journal: Journal of the General Practice Airways Group, 2010, 19, 408-408.	2.5	27
439	Observational study comparing intranasal mometasone furoate with oral antihistamines for rhinitis and asthma. Primary Care Respiratory Journal: Journal of the General Practice Airways Group, 2010, 19, 266-273.	2.5	14
440	The feasibility of recruiting patients with early COPD to a pilot trial assessing the effects of a physical activity intervention. Primary Care Respiratory Journal: Journal of the General Practice Airways Group, 2010, 19, 124-130.	2.5	28
441	What happens to patients who have their asthma device switched without their consent?. Primary Care Respiratory Journal: Journal of the General Practice Airways Group, 2010, 19, 131-139.	2.5	53
442	Suboptimal persistence with inhaled corticosteroid monotherapy among children with persistent asthma in the UK. Primary Care Respiratory Journal: Journal of the General Practice Airways Group, 2010, 20, 97-101.	2.5	4
443	The use of roflumilast in COPD: a primary care perspective. Primary Care Respiratory Journal: Journal of the General Practice Airways Group, 2010, 19, 342-351.	2.5	19
444	Community pharmacy provision of allergic rhinitis treatments: a longitudinal study of patient reported outcome. International Journal of Pharmacy Practice, 2010, 13, 249-256.	0.3	6
445	Choosing inhaler devices for people with asthma: Current knowledge and outstanding research needs. Respiratory Medicine CME, 2010, 3, 125-131.	0.1	20
446	From support to boundary: A qualitative study of the border between self-care and professional care. Patient Education and Counseling, 2010, 79, 55-61.	1.0	62
447	Improved adherence with once-daily versus twice-daily dosing of mometasone furoate administered via a dry powder inhaler: a randomized open-label study. BMC Pulmonary Medicine, 2010, 10, 1.	0.8	128
448	Improving clinician–patient communication in asthma: the HARP project. Allergy: European Journal of Allergy and Clinical Immunology, 2010, 65, 413-414.	2.7	7
449	Development and implementation of guidelines in allergic rhinitis – an ARIAâ€GA ² LEN paper. Allergy: European Journal of Allergy and Clinical Immunology, 2010, 65, 1212-1221.	2.7	85
450	Cost-effectiveness analysis of corticosteroid inhaler devices in primary care asthma management: A real world observational study. ClinicoEconomics and Outcomes Research, 2010, 2, 75.	0.7	15

#	Article	IF	CITATIONS
451	A Review of the Evidence of Third Sector Performance and Its Relevance for a Universal Comprehensive Health System. Social Policy and Society, 2010, 9, 515-526.	0.7	19
452	Asthma and allergic rhinitis: Linked in treatment and outcomes. Annals of Thoracic Medicine, 2010, 5, 63.	0.7	21
453	Improving the Differential Diagnosis of Chronic Obstructive Pulmonary Disease in Primary Care. Mayo Clinic Proceedings, 2010, 85, 1122-1129.	1.4	42
454	Prescribing practices and asthma control with hydrofluoroalkane-beclomethasone and fluticasone: AÂreal-world observational study. Journal of Allergy and Clinical Immunology, 2010, 126, 511-518.e10.	1.5	72
455	Allergic Rhinitis and its Impact on Asthma (ARIA) guidelines: 2010 Revision. Journal of Allergy and Clinical Immunology, 2010, 126, 466-476.	1.5	1,322
456	Inhalation by Design: Novel Ultra-Long-Acting β ₂ -Adrenoreceptor Agonists for Inhaled Once-Daily Treatment of Asthma and Chronic Obstructive Pulmonary Disease That Utilize a Sulfonamide Agonist Headgroup. Journal of Medicinal Chemistry, 2010, 53, 6640-6652.	2.9	72
457	Choosing inhaler devices for people with asthma: Current knowledge and outstanding research needs. Respiratory Medicine, 2010, 104, 1237-1245.	1.3	146
458	BODE plus DOSE plus PaO2equals DO RE MI BOX?. American Journal of Respiratory and Critical Care Medicine, 2010, 182, 1089-1089.	2.5	5
459	Cost Effectiveness of Leukotriene Receptor Antagonists versus Inhaled Corticosteroids for Initial Asthma Controller Therapy. Pharmacoeconomics, 2010, 28, 585-595.	1.7	9
460	Cost Effectiveness of Leukotriene Receptor Antagonists versus Long-Acting Beta-2 Agonists as Add-On Therapy to Inhaled Corticosteroids for Asthma. Pharmacoeconomics, 2010, 28, 597-608.	1.7	14
461	Patient preferences for inhaler devices in chronic obstructive pulmonary disease: experience with Respimat® Soft Mist™ Inhaler. International Journal of COPD, 2009, 4, 381.	0.9	95
462	The commercialisation of GP services: a survey of APMS contracts and new GP ownership. British Journal of General Practice, 2009, 59, e339-e343.	0.7	10
463	Antibiotic Prescribing and Outcomes of Lower Respiratory Tract Infection in UK Primary Care. Chest, 2009, 135, 1163-1172.	0.4	44
464	Predictors of asthma control in everyday clinical practice in Switzerland. Current Medical Research and Opinion, 2009, 25, 2549-2555.	0.9	18
465	The CYMPLA trial. Mobile phone-based strrctrred intervention to achieve asthma control in patients with rncontrolled persistent asthma: a pragmatic randomised controlled trial. Primary Care Respiratory Journal: Journal of the General Practice Airways Group, 2009, 18, 343-345.	2.5	17
466	Prescribing trends in asthma: a longitudinal observational study. Archives of Disease in Childhood, 2009, 94, 16-22.	1.0	47
467	Derivation and Validation of a Composite Index of Severity in Chronic Obstructive Pulmonary Disease. American Journal of Respiratory and Critical Care Medicine, 2009, 180, 1189-1195.	2.5	228
468	Befriending carers of people with dementia: a cost utility analysis. International Journal of Geriatric Psychiatry, 2009, 24, 610-623.	1.3	29

#	Article	IF	CITATIONS
469	Inhaled corticosteroids for asthma: impact of practice level device switching on asthma control. BMC Pulmonary Medicine, 2009, 9, 1.	0.8	111
470	An economic evaluation of NIOX MINO airway inflammation monitor in the United Kingdom. Allergy: European Journal of Allergy and Clinical Immunology, 2009, 64, 431-438.	2.7	37
471	What you need to know about inhalers and how to use them. The Prescriber, 2009, 20, 47-52.	0.1	16
472	High-dose inhaled corticosteroids versus add-on long-acting β-agonists in asthma: An observational study. Journal of Allergy and Clinical Immunology, 2009, 123, 116-121.e10.	1.5	54
473	â€~Real-Life' Effectiveness of Qvar, Beclomethasone and Fluticasone. Journal of Allergy and Clinical Immunology, 2009, 123, 729.	1.5	5
474	Unmet needs in severe chronic upper airway disease (SCUAD). Journal of Allergy and Clinical Immunology, 2009, 124, 428-433.	1.5	191
475	01-P013 Overlooked: MicroRNAs acting by full & near full complementarity in mammals. Mechanisms of Development, 2009, 126, S54-S55.	1.7	0
476	12-P018 Investigating the mechanism by which thalamocortical projections reach the cerebral cortex in the mouse. Mechanisms of Development, 2009, 126, S194.	1.7	0
477	13-P140 The role of Pax6 in morphological and molecular development of thalamus and prethalamus. Mechanisms of Development, 2009, 126, S236.	1.7	0
478	The Asthma Control TestTM (ACT) as a predictor of GINA guideline-defined asthma control: analysis of a multinational cross-sectional survey. Primary Care Respiratory Journal: Journal of the General Practice Airways Group, 2009, 18, 41-49.	2.5	231
479	Biochemical properties, pharmacokinetics and pharmacological response of tiotropium in chronic obstructive pulmonary disease patients. Expert Opinion on Drug Metabolism and Toxicology, 2009, 5, 417-424.	1.5	21
480	Screening for and early detection of chronic obstructive pulmonary disease. Lancet, The, 2009, 374, 721-732.	6.3	303
481	Not all asthma inhalers are the same: factors to consider when prescribing an inhaler. Primary Care Respiratory Journal: Journal of the General Practice Airways Group, 2009, 18, 243-249.	2.5	104
482	Guidelines for allergic rhinitis need to be used in primary care. Primary Care Respiratory Journal: Journal of the General Practice Airways Group, 2009, 18, 250-257.	2.5	31
483	The value of self-report assessment of adherence, rhinitis and smoking in relation to asthma control. Primary Care Respiratory Journal: Journal of the General Practice Airways Group, 2009, 18, 300-305.	2.5	142
484	Spirometry in primary care case-identification, diagnosis and management of COPD. Primary Care Respiratory Journal: Journal of the General Practice Airways Group, 2009, 18, 216-223.	2.5	58
485	Driving asthma care in Europe: the Brussels Declaration. Primary Care Respiratory Journal: Journal of the General Practice Airways Group, 2009, 18, 55-56.	2.5	1
486	Flawed Comparative Groups Lead to Flawed Conclusions: Response. Chest, 2009, 136, 1185-1186.	0.4	0

#	Article	IF	CITATIONS
487	Allergic Rhinitis and its Impact on Asthma (ARIA) 2008*. Allergy: European Journal of Allergy and Clinical Immunology, 2008, 63, 8-160.	2.7	3,827
488	Comparison of Mometasone Furoate Dry Powder Inhaler and Fluticasone Propionate Dry Powder Inhaler in Patients with Moderate to Severe Persistent Asthma Requiring High-Dose Inhaled Corticosteroid Therapy: Findings from a Noninferiority Trial. Journal of Asthma, 2008, 45, 215-220.	0.9	10
489	Achieving asthma control in practice: Understanding the reasons for poor control. Respiratory Medicine, 2008, 102, 1681-1693.	1.3	199
490	British Guideline on the Management of Asthma. Thorax, 2008, 63, iv1-iv121.	2.7	655
491	Breathing exercises for asthma: a randomised controlled trial. Thorax, 2008, 64, 55-61.	2.7	119
492	Has the NAO Audited Risk Transfer in Operational Private Finance Initiative Schemes?. Public Money and Management, 2008, 28, 173-178.	1.2	17
493	Befriending carers of people with dementia: randomised controlled trial. BMJ: British Medical Journal, 2008, 336, 1295-1297.	2.4	62
494	The Brussels Declaration: the need for change in asthma management. European Respiratory Journal, 2008, 32, 1433-1442.	3.1	96
495	Impact of comorbidities on asthma. Expert Review of Clinical Immunology, 2008, 4, 731-742.	1.3	16
496	The use of omalizumab in asthma. Primary Care Respiratory Journal: Journal of the General Practice Airways Group, 2008, 17, 62-72.	2.5	36
497	EPOS Primary Care Guidelines: European Position Paper on the Primary Care Diagnosis and Management of Rhinosinusitis and Nasal Polyps 2007 — a summary. Primary Care Respiratory Journal: Journal of the General Practice Airways Group, 2008, 17, 79-89.	2.5	154
498	The current burden of allergic rhinitis amongst primary care practitioners and its impact on patient management. Primary Care Respiratory Journal: Journal of the General Practice Airways Group, 2008, 18, 27-33.	2.5	16
499	Perceptions, impact and management of asthma in South Africa: a patient questionnaire study. Primary Care Respiratory Journal: Journal of the General Practice Airways Group, 2008, 17, 212-216.	2.5	12
500	Comparison of tiotropium bromide and combined ipratropium/salbutamol for the treatment of COPD: a UK General Practice Research Database 12-month follow-up study. Primary Care Respiratory Journal: Journal of the General Practice Airways Group, 2008, 17, 104-110.	2.5	25
501	Pro-con debate: Inhaled corticosteroids should not be prescribed in primary care to children under two years of age — the case for. Primary Care Respiratory Journal: Journal of the General Practice Airways Group, 2008, 17, 176-180.	2.5	3
502	Statistical correlation between geophysical logs and extracted core. Geophysics, 2008, 73, E97-E106.	1.4	5
503	Short-Course Montelukast for Intermittent Asthma in Children. American Journal of Respiratory and Critical Care Medicine, 2007, 175, 323-329.	2.5	202
504	An Examination of the UK Treasury's Evidence Base for Cost and Time Overrun Data in UK Value-for-Money Policy and Appraisal. Public Money and Management, 2007, 27, 127-134.	1.2	64

#	Article	IF	CITATIONS
505	Developmental Cell Death Is Enhanced in the Cerebral Cortex of Mice Lacking the Brain Vesicular Monoamine Transporter. Journal of Neuroscience, 2007, 27, 1315-1324.	1.7	43
506	Cost-effectiveness of salmeterol xinafoate/fluticasone propionate combination inhaler in chronic asthma. Current Medical Research and Opinion, 2007, 23, 1147-1159.	0.9	18
507	Treatment and Outcomes in Patients with Asthma and Allergic Rhinitis in the United Kingdom. International Archives of Allergy and Immunology, 2007, 142, 318-328.	0.9	15
508	COPD screening efforts in primary care: what is the yield?. Primary Care Respiratory Journal: Journal of the General Practice Airways Group, 2007, 16, 41-48.	2.5	96
509	The impact of asthma exacerbations on health-related quality of life in moderate to severe asthma patients in the UK. Primary Care Respiratory Journal: Journal of the General Practice Airways Group, 2007, 16, 22-27.	2.5	126
510	The UK General Practice Airways Group (GPIAG): its formation, development, and influence on the management of asthma and other respiratory diseases over the last twenty years. Primary Care Respiratory Journal: Journal of the General Practice Airways Group, 2007, 16, 132-139.	2.5	10
511	Concerns of patients with allergic rhinitis: the Allergic Rhinitis Care Programme in South Africa. Primary Care Respiratory Journal: Journal of the General Practice Airways Group, 2007, 16, 299-303.	2.5	22
512	The use of a modification of the Patient Enablement Instrument in asthma. Primary Care Respiratory Journal: Journal of the General Practice Airways Group, 2007, 16, 89-92.	2.5	31
513	Do people self-reporting information about chronic respiratory disease have corroborative evidence in their general practice medical records? A study of intermethod reliability. Primary Care Respiratory Journal: Journal of the General Practice Airways Group, 2007, 16, 162-168.	2.5	34
514	An exploratory, pragmatic, cluster randomised trial of practice nurse training in the use of asthma action plans. Primary Care Respiratory Journal: Journal of the General Practice Airways Group, 2007, 16, 311-318.	2.5	20
515	Concerns of patients with allergic rhinitis: the Allergic Rhinitis Care Programme in South Africa. Primary Care Respiratory Journal: Journal of the General Practice Airways Group, 2007, 16, 1-1.	2.5	2
516	The market in primary care. BMJ: British Medical Journal, 2007, 335, 475-477.	2.4	26
517	Beclometasone dipropionate extrafine aerosol versus fluticasone propionate in children with asthma. Respiratory Medicine, 2007, 101, 1585-1593.	1.3	23
518	Efficacy and safety of tiotropium in COPD patients in primary care – the SPiRiva Usual CarE (SPRUCE) study. Respiratory Research, 2007, 8, 45.	1.4	51
519	Salmeterol/fluticasone stable-dose treatment compared with formoterol/budesonide adjustable maintenance dosing: impact on health-related quality of life. Respiratory Research, 2007, 8, 46.	1.4	19
520	Practice development plans to improve the primary care management of acute asthma: randomised controlled trial. BMC Family Practice, 2007, 8, 23.	2.9	18
521	Can asthma control be improved by understanding the patient's perspective?. BMC Pulmonary Medicine, 2007, 7, 8.	0.8	167
522	Costâ€effectiveness of budesonide/formoterol for maintenance and reliever asthma therapy. Allergy: European Journal of Allergy and Clinical Immunology, 2007, 62, 1189-1198.	2.7	50

#	Article	IF	CITATIONS
523	Common characteristics of upper and lower airways in rhinitis and asthma: ARIA update, in collaboration with GA ² LEN. Allergy: European Journal of Allergy and Clinical Immunology, 2007, 62, 1-41.	2.7	233
524	Standardized training for healthcare professionals and its impact on patients with perennial rhinitis: a multi-centre randomized controlled trial. Clinical and Experimental Allergy, 2007, 37, 90-99.	1.4	26
525	Understanding the potential role of mobile phone-based monitoring on asthma self-management: qualitative study. Clinical and Experimental Allergy, 2007, 37, 794-802.	1.4	94
526	Co-morbid disease in COPDmore than a coincidence. International Journal of COPD, 2007, 2, 399-400.	0.9	1
527	Misdiagnosis of COPD and Asthma in Primary Care Patients 40 Years of Age and Over. Journal of Asthma, 2006, 43, 75-80.	0.9	229
528	Sub-optimal patient and physician communication in primary care consultations: its relation to severe and difficult asthma. Primary Care Respiratory Journal: Journal of the General Practice Airways Group, 2006, 15, 159-165.	2.5	28
529	Comorbidity among the morbidly obese: a comparative study of 2002 U.S. hospital patient discharges. Surgery for Obesity and Related Diseases, 2006, 2, 105-111.	1.0	23
530	Professional and patient attitudes to using mobile phone technology to monitor asthma: questionnaire survey. Primary Care Respiratory Journal: Journal of the General Practice Airways Group, 2006, 15, 237-245.	2.5	61
531	Exacerbations of chronic obstructive pulmonary disease — A patients' perspective. Primary Care Respiratory Journal: Journal of the General Practice Airways Group, 2006, 15, 102-109.	2.5	34
532	High-dose inhaled corticosteroids and add-on therapy use in adults with asthma in the UK in 2003: an observational study. Primary Care Respiratory Journal: Journal of the General Practice Airways Group, 2006, 15, 166-172.	2.5	16
533	International Primary Care Respiratory Group (IPCRG) Guidelines: Diagnosis of respiratory diseases in primary care. Primary Care Respiratory Journal: Journal of the General Practice Airways Group, 2006, 15, 20-34.	2.5	126
534	International Primary Care Respiratory Group (IPCRG) Guidelines: Management of allergic rhinitis. Primary Care Respiratory Journal: Journal of the General Practice Airways Group, 2006, 15, 58-70.	2.5	114
535	ARIA update: l—Systematic review of complementary and alternative medicine for rhinitis and asthma. Journal of Allergy and Clinical Immunology, 2006, 117, 1054-1062.	1.5	141
536	Scoring System and Clinical Application of COPD Diagnostic Questionnaires. Chest, 2006, 129, 1531-1539.	0.4	155
537	Improving outcomes for asthma patients with allergic rhinitis: the MetaForum conferences. BMC Pulmonary Medicine, 2006, 6, 1.	0.8	17
538	Asthma out of control? A structured review of recent patient surveys. BMC Pulmonary Medicine, 2006, 6, S2.	0.8	63
539	Breaking new ground: challenging existing asthma guidelines. BMC Pulmonary Medicine, 2006, 6, S6.	0.8	43
540	Improving outcomes for asthma patients with allergic rhinitis: conclusions from the MetaForum conferences. BMC Pulmonary Medicine, 2006, 6, S7.	0.8	2

#	Article	IF	CITATIONS
541	Effect of montelukast on lung function in asthma patients with allergic rhinitis: analysis from the COMPACT trial. Allergy: European Journal of Allergy and Clinical Immunology, 2006, 61, 737-742.	2.7	116
542	Pharmacologic and anti-IgE treatment of allergic rhinitis ARIA update (in collaboration with GA2LEN). Allergy: European Journal of Allergy and Clinical Immunology, 2006, 61, 1086-1096.	2.7	123
543	Impact of antibiotic restrictions: the physician's perspective. Clinical Microbiology and Infection, 2006, 12, 3-9.	2.8	11
544	Can a GP be a generalist and a specialist? Stakeholders views on a respiratory General Practitioner with a special interest service in the UK. BMC Health Services Research, 2006, 6, 62.	0.9	18
545	Primary care and palliative care. BMJ: British Medical Journal, 2006, 333, 188-190.	2.4	16
546	Poor communication may impair optimal asthma care: a qualitative study. Family Practice, 2006, 24, 65-70.	0.8	48
547	Symptom-Based Questionnaire for Differentiating COPD and Asthma. Respiration, 2006, 73, 296-305.	1.2	72
548	Symptom-Based Questionnaire for Identifying COPD in Smokers. Respiration, 2006, 73, 285-295.	1.2	192
549	The effect of tiotropium bromide on health-related quality of life in chronic obstructive pulmonary disease. Expert Review of Pharmacoeconomics and Outcomes Research, 2006, 6, 391-405.	0.7	1
550	Diagnosis of airway obstruction in primary care in the UK: the CADRE (COPD and Asthma) Tj ETQq0 0 0 rgBT /O 435-443.	verlock 10 0.9	0 Tf 50 387 Td 22
551	A pragmatic, three-arm randomised controlled trial of spiritual healing for asthma in primary care. British Journal of General Practice, 2006, 56, 444-9.	0.7	12
552	Privatising primary care. British Journal of General Practice, 2006, 56, 565-6.	0.7	10
553	High-dose inhaled corticosteroid use in childhood asthma: an observational study of GP prescribing. British Journal of General Practice, 2006, 56, 788-90.	0.7	13
554	Gastroesophageal Reflux Disease and Asthma. Chest, 2005, 128, 85-93.	0.4	75
555	Is Living in a Rural Area Good for Your Respiratory Health?. Chest, 2005, 128, 2059-2067.	0.4	52
556	Asthma-Related Health Care Resource Use Among Asthmatic Children With and Without Concomitant Allergic Rhinitis. Pediatrics, 2005, 115, 129-134.	1.0	132
557	Foreword: Can dry powder inhalers be used interchangeably?. International Journal of Clinical Practice, 2005, 59, 1-1.	0.8	1
558	Could interchangeable use of dry powder inhalers affect patients?. International Journal of Clinical Practice, 2005, 59, 3-6.	0.8	17

#	Article	IF	CITATIONS
559	Do healthcare professionals think that dry powder inhalers can be used interchangeably?. International Journal of Clinical Practice, 2005, 59, 26-29.	0.8	15
560	The way forward: dry powder inhalers should only be switched with physician agreement and patient training. International Journal of Clinical Practice, 2005, 59, 36-37.	0.8	10
561	Effect of a concomitant diagnosis of allergic rhinitis on asthma-related health care use by adults. Clinical and Experimental Allergy, 2005, 35, 282-287.	1.4	176
562	General practitioners with a special interest in respiratory medicine: national survey of UK primary care organisations. BMC Health Services Research, 2005, 5, 40.	0.9	17
563	Mobile phone technology in the management of asthma. Journal of Telemedicine and Telecare, 2005, 11, 43-46.	1.4	117
564	Budesonide/formoterol maintenance and reliever therapy: an effective asthma treatment option?. European Respiratory Journal, 2005, 26, 819-828.	3.1	189
565	Progressive breathlessness in COPD — The role of hyperinflation and its pharmacological management. Primary Care Respiratory Journal: Journal of the General Practice Airways Group, 2005, 14, 285-293.	2.5	6
566	Achieving optimal asthma control: Can this be informed by recent studies of professional-patient communication?. Primary Care Respiratory Journal: Journal of the General Practice Airways Group, 2005, 14, 233-235.	2.5	3
567	The prevalence of dysfunctional breathing in adults in the community with and without asthma. Primary Care Respiratory Journal: Journal of the General Practice Airways Group, 2005, 14, 78-82.	2.5	116
568	Questions for COPD diagnostic screening in a primary care setting. Respiratory Medicine, 2005, 99, 1311-1318.	1.3	58
569	The national montelukast survey. Journal of Allergy and Clinical Immunology, 2005, 115, 47-54.	1.5	46
570	Tackling a hidden epidemic. Independent Nurse, 2005, 2005, .	0.0	0
571	Cost-effectiveness of telephone or surgery asthma reviews: economic analysis of a randomised controlled trial. British Journal of General Practice, 2005, 55, 119-24.	0.7	32
572	Clinical management. Getting up to scratch. The Health Service Journal, 2005, 115, 30-2.	0.0	0
573	An economic evaluation of adjustable and fixed dosing with budesonide/formoterol via a single inhaler in asthma patients: the ASSURE study. Current Medical Research and Opinion, 2004, 20, 1671-1679.	0.9	16
574	Patients' perceptions of well-being using a guided self-management plan in asthma. International Journal of Clinical Practice, 2004, 58, 26-32.	0.8	8
575	Inadequacies in UK primary care allergy services: national survey of current provisions and perceptions of need. Clinical and Experimental Allergy, 2004, 34, 518-519.	1.4	40
576	Adjustable and fixed dosing with budesonide/formoterol via a single inhaler in asthma patients: the ASSURE study. Respiratory Medicine, 2004, 98, 464-475.	1.3	57

#	Article	IF	CITATIONS
577	Community-acquired pneumonia mortality: a potential link to antibiotic prescribing trends in general practice. Respiratory Medicine, 2004, 98, 17-24.	1.3	63
578	Development of a primary-care tool to assess treatment success in COPD: consensus report from a closed meeting of respiratory and primary-care specialists. Primary Care Respiratory Journal: Journal of the General Practice Airways Group, 2004, 13, 99-104.	2.5	1
579	Requirements for medications commonly used in the treatment of allergic rhinitis. European Academy of Allergy and Clinical Immunology (EAACI) Allergic Rhinitis and its Impact on Asthma (ARIA). Allergy: European Journal of Allergy and Clinical Immunology, 2003, 58, 192-197.	2.7	133
580	Breathing retraining for dysfunctional breathing in asthma: a randomised controlled trial. Thorax, 2003, 58, 110-115.	2.7	178
581	Improvement of asthma control with a breath-actuated pressurised metred dose inhaler (BAI): a prescribing claims study of 5556 patients using a traditional pressurised metred dose inhaler (MDI) or a breath-actuated device. Respiratory Medicine, 2003, 97, 12-19.	1.3	54
582	Pharmacoeconomics of asthma treatment. Expert Opinion on Pharmacotherapy, 2003, 4, 311-318.	0.9	11
583	Randomised controlled trial of montelukast plus inhaled budesonide versus double dose inhaled budesonide in adult patients with asthma. Thorax, 2003, 58, 211-216.	2.7	182
584	Database studies in asthma pharmacoeconomics: uses, limitations and quality markers. Expert Opinion on Pharmacotherapy, 2003, 4, 351-358.	0.9	25
585	Accessibility, acceptability, and effectiveness in primary care of routine telephone review of asthma: pragmatic, randomised controlled trial. BMJ: British Medical Journal, 2003, 326, 477-479.	2.4	120
586	Chronic obstructive pulmonary disease. BMJ: British Medical Journal, 2003, 326, 1046-1047.	2.4	25
587	A pilot study to assess the feasibility and acceptability of undertaking acute asthma professional development in three different UK primary care settings. Primary Care Respiratory Journal: Journal of the General Practice Airways Group, 2003, 12, 7-11.	2.5	6
588	Pragmatic research tales: The ELEVATE study as an illustration of the issues involved in implementing pragmatic research. Primary Care Respiratory Journal: Journal of the General Practice Airways Group, 2003, 12, 95-95.	2.5	0
589	Chronic cough. BMJ: British Medical Journal, 2003, 326, 1036-1036.	2.4	4
590	Prenatal antibiotic exposure and subsequent atopy. American Journal of Respiratory and Critical Care Medicine, 2003, 167, 1578-1579.	2.5	12
591	Routine telephone review of asthma: Authors' reply. BMJ: British Medical Journal, 2003, 326, 1267-c-1268.	2.4	0
592	The pharmacoepidemiology of COPD: recent advances and methodological discussion. The European Respiratory Journal Supplement, 2003, 43, 1s-44s.	0.8	17
593	Early asthma control and maintenance with eformoterol following reduction of inhaled corticosteroid dose. Thorax, 2002, 57, 791-798.	2.7	49
594	Clinically Important Improvements in Asthma-Specific Quality of Life, But No Difference in Conventional Clinical Indexes in Patients Changed From Conventional Beclomethasone Dipropionate to Approximately Half the Dose of Extrafine Beclomethasone Dipropionate. Chest, 2002, 121, 1824-1832.	0.4	116

#	Article	IF	CITATIONS
595	The burden of paediatric asthma is higher than health professionals think: results from the Asthma in Real Life (AIR) study. Primary Care Respiratory Journal: Journal of the General Practice Airways Group, 2002, 11, 30-33.	2.5	17
596	Pragmatic randomised controlled trials. Primary Care Respiratory Journal: Journal of the General Practice Airways Group, 2002, 11, 78-78.	2.5	1
597	General practitioners' understanding of severe and difficult asthma: A qualitative study. Primary Care Respiratory Journal: Journal of the General Practice Airways Group, 2002, 11, 99-102.	2.5	2
598	Cost Effectiveness of Asthma Management Strategies. Pharmacoeconomics, 2002, 20, 789.	1.7	4
599	Developmental expression of monoamine oxidases A and B in the central and peripheral nervous systems of the mouse. Journal of Comparative Neurology, 2002, 442, 331-347.	0.9	84
600	Executive Summary of the Workshop Report 7-10 December 1999, Geneva, Switzerland. Allergy: European Journal of Allergy and Clinical Immunology, 2002, 57, 841-855.	2.7	208
601	The Cost Effectiveness of Chlorofluorocarbon-Free Beclomethasone Dipropionate in the Treatment of Chronic Asthma. Pharmacoeconomics, 2002, 20, 653-664.	1.7	16
602	General practitioners with a special clinical interest: a model for improving respiratory disease management. British Journal of General Practice, 2002, 52, 838-43.	0.7	12
603	Training Issues in the Use of Inhalers. Disease Management and Health Outcomes, 2001, 9, 75-87.	0.3	23
604	Changes in asthma drug therapy costs for patients receiving chronic montelukast therapy in the U.K Respiratory Medicine, 2001, 95, 83-89.	1.3	23
605	Use of Montelukast in tapering inhaled corticosteroid therapy: an open-label, 48-week trial. Current Therapeutic Research, 2001, 62, 743-755.	0.5	7
606	Health care utilisation for respiratory symptoms. Primary Care Respiratory Journal: Journal of the General Practice Airways Group, 2001, 10, 56-57.	2.5	1
607	Guided self management plans for asthma. BMJ: British Medical Journal, 2001, 322, 1121-1121.	2.4	6
608	Guided self management plans for asthma. Advice should be simple and patient focused. BMJ: British Medical Journal, 2001, 322, 1121-2; author reply 1123.	2.4	2
609	Tolerability of Montelukast. Drugs, 2000, 59, 35-42.	4.9	28
610	Fluticasone propionate: an audit of outcomes and cost-effectiveness in primary care. Respiratory Medicine, 1998, 92, 351-353.	1.3	19
611	Salmeterol xinafoate: an analysis of outcomes and cost-effectiveness using a primary care database. Respiratory Medicine, 1998, 92, 1302-1304.	1.3	6
612	Concerns and misconceptions regarding steroid therapy in asthma: findings and impact of a public meeting. Primary Care Respiratory Journal: Journal of the General Practice Airways Group, 1998, 6, 43-44.	2.5	1

#	Article	IF	CITATIONS
613	A Within-Patient Comparison of Subcutaneous and Oral Sumatriptan in the Acute Treatment of Migraine in General Practice. Cephalalgia, 1997, 17, 31-36.	1.8	30
614	Occupational asthma in a new employee. Practitioner, 1996, 240, 619-22, 625.	0.3	0
615	Screening and case finding. , 0, , 1-25.		0
616	CONQUEST: A Quality Improvement Program for Defining and Optimizing Standards of Care for Modifiable High-Risk COPD Patients. Patient Related Outcome Measures, 0, Volume 13, 53-68.	0.7	3
617	Characterisation of the Australian Adult Population Living with Asthma: Severe - Exacerbation Frequency, Long-Term OCS Use and Adverse Effects. Journal of Pragmatic and Observational Research, O, Volume 13, 43-58.	1.1	5